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Lymphocyte subpopulations, particularly regulatory T-cells (Tregs), have been extensively studied in 
the last few years. Tregs are T-cells with an immunosuppressive role, responsible for the expression of 
regulatory cytokines like IL-10 and TGF-β. A reduction of circulating Treg levels has been associated 
with various auto-immune diseases, especially in active disease. As for non-infectious uveitis (NIU), 
results have been conflicting, and further studies are needed to better understand the role of the 
frequency and function of total Treg and subsets in NIU.  
The present thesis aimed to analyze the lymphocyte subpopulations, especially Tregs, as well as 
inflammatory and anti-inflammatory cytokines in patients with active NIU and compare them with 
normal controls. One subgroup of NIU patients was further evaluated after treatment and uveitis 
resolution. Later on, in infectious uveitis (IU) patients, aqueous humour (AqH) samples were also 
analyzed for cytokine characterization.  
In active NIU, we found no significant differences in Treg levels (including naïve and memory subsets) 
between patients and controls. In NIU patients evaluated over time, our results showed an increased 
percentage of both total and memory Tregs in patients with active inflammation, without significant 
difference from controls after treatment. Nevertheless, it is interesting that this initial increase in total 
and memory Treg percentages was not associated with an increased CD39 expression, which may lead 
us to speculate whether these cells maintained their normal suppressive function. 
When comparing serum cytokine levels in NIU patients and controls, our results showed a tendency 
for IL-17A elevation in the NIU group and positive correlations between the inflammatory (TNF-α + 
IFN-ɣ + IL-17A) /anti-inflammatory (IL-10 + TGF-β) cytokine ratio and the IL-17/IL-10 ratio with the 
absolute counts of memory Tregs. We also found that higher IL-17A levels were associated with higher 
serum concentrations of memory and naïve Tregs as well as higher TNF-α and IFN-ɣ levels.  After 
treatment, lower levels of IL-17A and TNF-α were present in patients in uveitis remission. Furthermore, 
the inflammatory/anti-inflammatory ratio also showed a significant reduction between evaluations.  
As for cytokine levels in IU patients, our results showed that while there were no significant differences 
between patients and controls regarding serum cytokine profiles, increased concentrations of IL-10, 
TNF-α, and IFN-ɣ in the AqH samples were found in patients diagnosed with varicella-zoster virus (VZV)-
associated uveitis. 





Our results do not support the role of total Treg frequency alone as a uveitis biomarker, and since, to 
our knowledge, these are the first studies addressing the role of Treg naïve and memory subsets and 
their respective CD39 expression in the peripheral blood of NIU patients, further studies should be 
addressed to elucidate the possible role of each subset in NIU pathogenesis and treatment. 
As for cytokine profiles in infectious and non-infectious uveitis, our results highlight the importance of 
IL-17 in active NIU and the possible association between elevated intraocular IL-10 levels and VZV-
associated infection.  
We hope that this work may contribute to finding new biomarkers for active intraocular inflammation 
and new therapeutic targets for future research.  
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As subpopulações linfocitárias, e em particular as células T reguladoras (Tregs), têm sido alvo de 
intensa investigação nos últimos anos. As Tregs são células reconhecidas pelo seu papel 
imunorregulador e responsáveis pela expressão de citocinas anti-inflamatórias como, por exemplo, a 
IL-10 e o TGF-β. A redução de níveis circulantes de Tregs tem sido associada a várias doenças auto-
imunes, particularmente em casos de doença activa. No caso da uveíte não-infecciosa (NIU), os 
resultados têm sido contraditórios, sendo necessários estudos adicionais para que se possa entender 
o papel definitivo da frequência e função das subpopulações de células Tregs na sua patogénese. 
O presente estudo tem como objectivo analisar as subpopulações linfocitárias, em especial a 
subpopulação Treg, bem como os perfis de citocinas inflamatórias e anti-inflamatórias circulantes de 
doentes com NIU activa, comparando-os com os de controlos normais. Há ainda a realçar a análise 
adicional de um subgrupo de doentes com NIU após tratamento e resolução da uveíte. Em doentes 
com uveíte infecciosa (IU) foram ainda analisadas amostras de humor aquoso (HAq), tendo em vista a 
caracterização de um perfil de citocinas.  
Em doentes com NIU activa não foram encontradas diferenças significativas nos níveis periféricos de 
Tregs (incluindo naïve e de memória) relativamente aos controlos. Em doentes avaliados ao longo do 
tempo, os nossos resultados mostraram um aumento das percentagens de Tregs totais e de memória, 
numa primeira avaliação, mas novamente sem diferença relativamente aos controlos após o 
tratamento. Ainda assim é interessante observar que este aumento inicial nas percentagens de Tregs 
totais e de memória não foi acompanhado de um aumento significativo na expressão de CD39, o que 
pode significar a perda da normal função supressora destas células.  
Relativamente aos níveis séricos de citocinas em doentes com NIU e controlos, os nossos resultados 
mostraram uma tendência para elevação da IL-17 no grupo com uveíte, bem como correlações 
positivas entre o ratio de citocinas inflamatórias (TNF-α + IFN-ɣ + IL-17) /anti-inflamatórias (IL-10 + 
TGF-β) e o ratio IL-17/IL-10 com as contagens absolutas de Tregs de memória. Para além disso, níveis 
séricos mais elevados de IL-17 mostraram uma associação com concentrações mais elevadas de Tregs 
naïve e de memória e ainda com níveis séricos mais elevados de TNF-α e de IFN-ɣ. 





Após tratamento, houve uma diminuição significativa nos níveis circulantes de IL-17 e de TNF-α no 
grupo de doentes com NIU em remissão, bem como uma redução significativa, entre avaliações, no 
ratio de citocinas inflamatórias/anti-inflamatórias. Por fim, no grupo de doentes com IU, os nossos 
resultados mostraram um aumento das concentrações de IL-10, TNF-α e IFN-ɣ no humor aquoso de 
doentes com infecção intraocular comprovada por vírus varicella zoster (VVZ). Já no sangue periférico, 
não se encontraram diferenças significativas entre perfis de citocinas de doentes e controlos 
saudáveis. 
Os nossos resultados não apoiam a utilização isolada da frequência periférica total de Tregs como um 
biomarcador de uveíte activa. Pensamos que este estudo é pioneiro na avaliação de subpopulações 
Treg naïve e de memória, e sua respectiva expressão CD39, no sangue periférico de doentes com NIU. 
No entanto, são necessários mais estudos para que o papel individual de cada uma destas 
subpopulações Treg na patogénese e eventual tratamento da NIU possa ser esclarecido.  
Relativamente aos perfis de citocinas em doentes com uveíte de causa infecciosa e não-infecciosa, este 
trabalho de investigação permite sublinhar a importância da citocina IL-17 na NIU activa e uma 
eventual associação entre níveis intraoculares elevados de IL-10 e a uveíte associada a infecção por 
VVZ.  
Estes resultados podem vir a contribuir para a identificação de biomarcadores de inflamação 
intraocular activa e na investigação de novos alvos terapêuticos. 
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1. Ocular Immune Privilege 
The eye is well known for favoring an immunosuppressive environment in an attempt to protect vision 
from a possible inflammatory reaction that may damage intraocular structures. Several mechanisms 
contribute to this immune privilege: (1) Physical barriers; (2) Anterior Chamber-Associated Immune 
Deviation (ACAID); and (3) Inhibitory Ocular Microenvironment. 
 
1.1 Physical barriers 
The eye is a complex organ with distinct anatomic structures and blood supplies that form blood–
ocular barriers. The blood-ocular barriers are highly specialized and selectively control the 
inward/toward crossing of compounds into the eye. There are two main blood-ocular barriers, the 
Blood-Aqueous Barrier (BAB) and the Blood-Retinal Barrier (BRB). 
The Blood-Aqueous Barrier is formed by endothelial cells of the iris's blood vessels and the ciliary 
epithelium's non-pigmented cell layer. Under normal conditions, only small molecules can penetrate 
the aqueous humor through the ciliary processes' fenestrated capillaries. A disruption of the zonula 
occludens between the non-pigmented ciliary cells causes a breakdown of the BAB and can occur in 
inflammatory conditions, allowing immune factors and leucocytes into the eye's anterior segment. 
The Blood-Retina Barrier consists of an inner and an outer component. The inner BRB is formed of tight 
junctions between retinal capillary endothelial cells and the outer BRB of tight junctions between 
Retinal Pigment Epithelial (RPE) cells (Fig. 4). Retinal edema, a frequent manifestation of retinal 
disease, is directly associated with a breakdown of the BRB and vision loss and can occur in retinal 










Fig. 1 - Tight junctions form the BRB at two sites: between endothelial cells of retinal vessels, that supply the 
inner retina (ganglion cells and bipolar cells), and the retinal pigment epithelium (RPE) cell, which filters blood 
from the fenestrated leaky choroidal vessels. (Author’s drawing) 
 





1.2 Anterior Chamber-Associated Immune Deviation (ACAID)  
ACAID is a down-regulation of delayed-type cellular immunity. Antigens released into the aqueous 
humour are presumably recognized by the iris and ciliary body's dendritic cells. Since there is a lack of 
efferent lymphatics in the eye, these antigen-presenting cells (APCs) can then enter the venous 
circulation and induce antigen-specific regulatory T cells in the spleen, bypassing the lymphatic system. 
Successful ACAID induction requires the antigen-bearing eye and an intact spleen to be in place for at 
least an initial 4- to 5-day interval, implying that a camero-splenic axis exists for the transfer of 
immunologically relevant information (1). The injection of an antigen into the anterior chamber 
induces a rise in Tumor Necrosis Factor α (TNF-α) and Monocyte Chemoattractant Protein-1 (MCP-1) 
in aqueous humour and an infiltration of circulating F4/80+ monocytes that home to the iris. The 
induction of ACAID is dependent on this infiltration of circulating monocytes that eventually emigrate 
to the thymus and spleen, where they induce regulatory T cells that inhibit the inductive or effector 
phases of a cell-mediated immune response (2) (Fig. 2). 
 
1.3 Inhibitory Ocular Microenvironment  
Suppression of immunogenic inflammation has been associated with immunosuppressive factors 
found in aqueous humour, which are produced by ocular tissues: 
Transforming Growth Factor-beta (TGF-β) 
Aqueous humour is capable of  altering the functional program of TCR-ligand-activated, primed T-cells, 
converting these cells into TGF-beta-producing regulatory T-cells (Tregs) (3); 
Neuropeptide Alpha-Melanocyte-Stimulating Hormone (α-MSH) 
Several immunomodulating neuropeptides are found in the aqueous humour and are produced by the 
RPE. The neuropeptide α-MSH has been demonstrated to have a critical central role in modulating 
immune activity within the eye (4), and the effects of aqueous humour on immune cells are very similar 










Fig. 2 - In the ACAID model, foreign antigens injected into the anterior chamber of the eye are captured by 
F4/80+ antigen-presenting cells (APCs) of the iris and ciliary body and travel via the blood to the spleen, where 
they promote the development of antigen-specific CD8+ Treg cells capable of suppressing delayed-type 
hypersensitivity responses toward eye-derived antigens. (Author’s drawing) 
 
 
Membrane-bound negative regulators 
T cells express regulatory activity when they come in contact with cultured RPE (6). Besides TGF-β and 
α-MSH, RPE cells express soluble cytotoxic T-lymphocyte antigen-2 α (CTLA-2α) and retinoic acid that 
promote regulatory activity (7). Besides, under conditions of inflammation, RPE cells express enhanced 
levels of Programmed Death-Ligand 1 (PDL1) and possibly major histocompatibility complex (MHC) 
class II (8), which also promote Treg cell activation. Moreover, cells throughout the ocular 
microenvironment express FasLigand (FasL), which has been suggested to be a significant contributor 
to immune privilege because its expression is necessary for graft survival within the eye (9).  The 
expression of PDL1 and FasL, along with the physical barrier created by the RPE and endothelial cells' 
tight junctions, form the immune barrier of the ocular microenvironment. 
Cellular negative regulators of inflammation 
The negative regulators of inflammation expressed within the eye suppress the production of 
proinflammatory cytokines and program immune cells to suppress inflammation and promote 
tolerance. 





The effects of aqueous humour on macrophages, the ACAID phenomena, and Treg cells' activation by 
retinal dendritic-like cells (10) demonstrate that antigen presentation within the immune-privileged 
eye does not follow conventional pathways that lead to effector T cell activation. The retina's microglial 
cells are potential cellular regulators of inflammation (11) and prevent T cell activation, and their 
immunosuppressive functions seem to be induced by the negative regulators produced by the RPE.  
Even though the eye is an immune-privileged tissue that has adapted several negative regulators to 
prevent the activation of inflammation within its tissue microenvironment, there are conditions in 
which this immune privilege fails. One of those conditions occurs in the presence of the intraocular 
inflammation caused by uveitis. The ocular tissues contain many potential autoantigenic targets, 
especially the retina, apparently sequestered from the immune system (12). The retina (containing 
retinal antigens) is formed early during embryogenesis, and the optic cup is closed by weeks 6 to 7. 
Lymphocytes of the B series develop in the liver by 9 weeks of gestation and are present in the blood 
and spleen by 12 weeks. T lymphocytes start to leave the thymus from about 14 weeks of gestation, 
and subsequently, cells with helper and suppressor phenotypes are present in the spleen. Sequestered 
retinal antigens are recognized as not-self and escape to the bloodstream after damage (trauma, 
infection, inherited degenerations), activating peripheral autoreactive T cells (13). Once activated, 
antigen-specific T cells enter the retina and eye tissues and attract pro-inflammatory macrophages, 
which cause more tissue damage (14).  
In experimental autoimmune-uveitis, inflammation declines inversely with an increase in Tregs, which 
accumulate and promote resolution. Immune privilege appears not to afford much protection against 
the damaging effects of uveitis, possibly because it works at the level of tissue homeostasis, mainly 
keeping healthy tissue free of random migrants, which might provoke inflammation (15). However, in 
uncontrolled uveitis, both infection and the immune response to infection can cause permanent 
structural damage. 
2. What is uveitis? 
Uveitis is the inflammation of the uvea, the pigmented vascular layer that lies between the inner retina 
and the outer fibrous layer composed of the sclera and cornea. The uvea consists of the middle layer 
of pigmented vascular structures of the eye and includes the iris, ciliary body, and choroid (Fig. 3). 
These distinct parts of the uvea can be affected separately: iris (Iritis), ciliary body (Cyclitis, 
Iridocyclitis), choroid (Choroiditis), or the entire uvea (Panuveitis). 






Fig. 3 - The uvea is the middle layer of the eye beneath the sclera. It is made up 
of the iris, ciliary body, and choroid. (Author’s drawing) 
 
Accordingly, uveitis is also sub-classified as Anterior Uveitis when it affects the anterior segment of the 
eye in which it is restricted to the anterior chamber, iris, and ciliary body; Intermediate Uveitis when 
it affects the pars plana region of the ciliary body (Pars Planitis) and the vitreous gel (Vitritis); Posterior 
Uveitis when inflammation affects the posterior segment of the eye including the retina (Retinitis), the 
retinal vessels (Vasculitis), the choroid (Choroiditis), or the optic nerve (papillitis, optic neuritis) and 
finally Panuveitis when both the anterior and posterior segments of the eye are affected. Table I 
summarizes the uveitis anatomical classification according to the Standardization of Uveitis 









Table I.  Anatomical Classification of Uveitis 
Type Primary Site of Inflammation Includes 
Anterior uveitis Anterior Chamber 
Iritis 
Iridocyclitis 
Intermediate Vitreous Pars Planitis 
Posterior Uveitis Retina and/or Choroid 











2.1. Clinical Features and Diagnosis 
Managing uveitis is often challenging and developing a differential diagnosis is the key to success. 
Classification of the uveitis and developing a list of potential diagnoses will help determine appropriate 
diagnostic testing, guide therapy, and help determine prognosis. Associated symptoms and signs are 
essential sources of information and require a systemic review of symptoms and a detailed physical 
examination. Referral to an internist, primary care physician, rheumatologist, or other specialist is 
often required in the work-up of uveitis. 
Ocular inflammation may be the initial presentation of an underlying systemic disease that, if 
undiagnosed and untreated, may lead to significant morbidity and even death.  
Diagnosis is mainly based on recognizing patterns that include findings from the medical history, 
clinical examination, laboratorial testing, and medical imaging. The first step in developing a 
differential diagnosis for patients with inflammatory eye disease is to classify the uveitis in as detailed 
a fashion as possible. 
 





2.1.1 Onset, duration, and course 
Uveitis must be classified in terms of onset, duration, and course (16) (Table II). The onset of uveitis 
should be described either as sudden or insidious. The duration of an attack of uveitis should be 
described as either limited (up to 3 months) or as persistent (more than 3 months). The term acute is 
used to describe the course of specific uveitic syndromes characterized by a sudden onset and limited 
duration, such as HLA-B27-associated uveitis. The term recurrent is used to describe repeated episodes 
of uveitis separated by periods of inactivity without treatment for at least 3 months. The term chronic 
is used to describe persistent uveitis characterized by prompt relapse (in less than 3 months) after 
therapy discontinuation. 
 
Table II.  Uveitis Classification regarding disease Onset, Duration and Course (SUN* Working Group) 






Limited  3 months duration 
Persistent > 3 months duration 
Course 
Acute Episode characterized by a sudden onset and limited duration 
Recurrent 
Repeated episodes separated by periods of inactivity without treatment for at 
least 3 months  
Chronic Persistent uveitis with relapse up to 3 months after discontinuing treatment 
*SUN=Standardization of Uveitis Nomenclature (16).  
 
Most occurrences of anterior uveitis, such as HLAB27-associated uveitis and idiopathic anterior uveitis, 
fall into this category. Other diseases that typically can cause acute uveitis include the Vogt–Koyanagi–
Harada (VKH) syndrome, Toxoplasmosis, Acute Posterior Multifocal Placoid Pigment Epitheliopathy 
(APMPPE), Multiple Evanescent White-Dot Syndrome (MEWDS), and traumatic iritis. Causes of chronic 
uveitis include Juvenile Idiopathic Arthritis, Birdshot Choroidopathy, Serpiginous Choroidopathy, 
Tuberculous uveitis, Sympathetic Ophthalmia, and Sarcoidosis. 
 






In anterior uveitis, inflammatory cells attach to the corneal endothelium in conglomerates called 
keratic precipitates (KPs). The appearance of KPs has been used to classify the inflammatory process 
as granulomatous or non-granulomatous. The more common non-granulomatous type of KP is 
characterized by fine white collections of lymphocytes, plasma cells, and pigment. Granulomatous KPs 
are large, greasy-appearing collections of lymphocytes, plasma cells, and giant cells. Patients with 
granulomatous KPs usually have a history of chronic disease with an insidious onset and frequently 
have posterior segment disease in addition to their anterior segment inflammation. Other ocular 
findings suggestive of granulomatous inflammation are iris nodules and choroidal granulomas. Causes 
of granulomatous uveitis are listed in Table III.   
 










2.1.3 Anterior Uveitis 
Anterior uveitis is much more common than intermediate, posterior, or panuveitis and accounts for 
85% of uveitis instances (18). It describes a disease limited predominantly to the anterior segment of 
the eye. The inflammation is characterized by conjunctival hyperemia, anterior chamber cell and flare, 
KPs, posterior synechiae, and peripheral anterior synechiae. A mild cellular inflammatory response in 
the anterior vitreous is often seen. 





The anterior chamber is easily examined with the slit lamp for signs of ocular inflammation. Since 
inflammatory cells do not arise in the aqueous, the presence of cells or increased protein (flare) in the 
anterior chamber is evidence of a spillover from the inflamed iris or ciliary body. Anterior chamber 
cells are best seen by directing the slit lamp beam obliquely across the eye and focusing posterior to 
the cornea. Although the cells' presence represents an index of activity, there is considerable variation 
among physicians on the grading of the number of cells. Nevertheless, the gradings for anterior 
chamber inflammation, anterior chamber cells and flare, according to the Standardization of Uveitis 
Nomenclature (SUN) (16) are summarized in Table IV and Table V. 
 
Table IV.  The SUN* Working Group Grading Scheme for Anterior Chamber Cells 















2+ Moderate (iris and lens details clear) 
3+ Marked (iris and lens details hazy) 
4+ Intense (fibrin or plastic aqueous) 
* SUN=Standardization of Uveitis Nomenclature 





The common causes of anterior uveitis are listed in Table VI 





Inflammatory Bowel Disease 
Psoriatic Arthritis 
Behçet’s Disease 
Juvenile Idiopathic Arthritis 
Fuchs’ Heterochromic Iridocyclitis 
Sarcoidosis 
Syphilis 




2.1.3.1 HLA-B27-Associated Uveitis 
Sudden onset anterior uveitis is the phenotype of uveitis typically associated with HLA-B27 (19). The 
frequency of uveitis varies with different forms of spondylarthritis. It will affect up to 50% of patients 
with ankylosing spondylitis (AS) in a lifetime (20), and it is the most common clinically significant co-
morbidity recognized among these patients (21). In Psoriatic Arthritis, the likelihood of uveitis 
association is 7 to 19% (22). This likelihood is lower still in association with either Crohn’s disease or 
Ulcerative Colitis (23).  





The connection between HLA-B27 and spondylarthritis has not yet been fully elucidated, although it is 
widely accepted that the entire intracellular process of HLA-B27 formation needs to be considered. 
There are some prevailing theories regarding the mechanism, including the hypothesis of molecular 
mimicry and the hypothesis of the cell-surface HLA-B27 homodimer. The molecular mimicry hypothesis 
posits that the antigenic components of infectious bacterial pathogens partially resembling or cross-
reacting with HLA molecules can stimulate CD8+T lymphocytes, followed by responding to one HLA-
B27 relevant self-peptide or the peptides directly produced by HLA-B27 (24). This hypothesis is 
primarily based on previously identified amino acid structures of homologous origin between the HLA 
structure and specific sequences of some bacterial antigens (25). The cell-surface HLA-B27 homodimer 
formation hypothesis is based on the fact that HLA-B27 heavy chains tend to form homodimers 
without beta-2 microglobulin via the disulfide bonds of the cysteine at C67 (26). The dimeric HLA-B27 
complexes, mostly found in patients' gut and synovium, may contribute to the genesis of AS and some 
other spondyloarthropathies. These HLA-B27 dimers could occur on APCs, thus stimulating the IL-23 
receptor on T-lymphocytes leading to the production of IL-17 (27). Moreover, HLA-B27 dimers might 
contribute to AS's development since they have been linked to receptors expressed on natural killer 
immunocytes, myelomonocytes, and lymphocytes. The binding is realized via killer cell 
immunoglobulin-like receptors and leucocyte immunoglobulin-like-receptors, thus acting in processes 
related to autoimmune disorders (28, 29). 
In HLA-B27 positive individuals, recurrent episodes of acute anterior uveitis (AAU) have been 
associated with increased ocular vascular permeability, which normalizes between episodes. This 
indicates that a temporary breakdown of the selectively permeable blood-aqueous barrier occurs 
during AAU episodes (30). 
HLA-B27 positive patients with systemic disease have a higher probability of recurrent uveitis episodes 
than those without systemic symptoms (31). However, uveitic activity may not always be related to 
the systemic disease activity (32), and the inflammatory rheumatologic manifestations seem to 
precede uveitis (33). The frequency of extraocular B27-associated disease is within the 30% to 90% 
range (34, 35).  Males seem to be 2 to 5 times more affected than females (36), and the mean age for 
the appearance of uveitis is in the range of 32 to 35.6 years in the literature (37, 38). 
The diagnosis of HLA-B27-associated uveitis is based on clinical features and positivity to HLA-B27 
antigen after the exclusion of other infectious or inflammatory diseases. 





Clinically, HLA-B27-positive AAU has an acute onset and is a unilateral alternating, non-granulomatous 
uveitis with a high tendency for recurrences with a mean number of 0.6 - 3.3 attacks per patient and 
per year of follow-up, and a mean duration of each episode of 4-6 weeks (39, 40). It is also 
characterized by sudden redness, blurring vision, pain, and photophobia (41). A relevant exudation in 
the anterior chamber is also present, hypopyon and fibrin can occur, and posterior synechiae may be 
observed.  
Ocular complications are common and are present in over 65% of HLA-B27-positive AAU patients (39). 
Frequent complications are listed in Table VII. 
Inflammation in HLA-B27-associated uveitis generally responds well to topical therapy with 
corticosteroids and cycloplegics. However, patients who present with hypopyon, a fibrinous reaction 
in the anterior chamber, pupillary seclusion, and/or macular edema may need additional periocular 
therapy with a subconjunctival or sub-tenon steroid injection or even oral corticosteroids. The need 
for immunosuppressive therapy is often associated with the incidence and gravity of extraocular 
manifestations or increased recurrence rate.   
Anterior uveitis is generally considered to be associated with a better visual prognosis than other 
uveitis forms such as panuveitis and posterior uveitis. In a study on the causes of visual impairment 
and blindness in intraocular inflammatory diseases, 10% of HLA-B27-associated anterior uveitis 
patients suffered legal blindness or severe visual impairment (42). However, a more recent study 
reported that, among a large case series of 175 patients with HLA-B27-associated uveitis, only 7% of 
patients demonstrated significantly decreased final visual acuity (2 lines) (40). 
 
Table VII. Ocular Complications in HLA-B27-Associated Uveitis 
Complication Frequency (31, 39, 40) 
Posterior synechiae 13-91% 
CataractA<SWXDCA<SWXDC\ 7-28% 
Ocular Hypertension/Glaucoma 7-20% / 2-12% 









2.1.3.2 Herpetic Uveitis (and Keratouveitis) 
Herpetic keratitis is probably the most common ocular disease associated with uveitis, and patients 
with stromal keratitis often have concurrent anterior uveitis. Although uveitis occurs during the initial 
onset of epithelial disease in some patients, most patients have uveitis with stromal involvement (43). 
Recurrent episodes are common and can severely damage the eye. Anterior uveitis may also occur in 
patients with a history of previous epithelial herpetic infection without currently active corneal 
disease. Herpetic keratouveitis manifests as a red, photophobic, and painful eye with decreased vision.  
This infection should be suspected in patients with a significant corneal opacity accompanied by 
synechiae, anterior chamber cells, large KPs, and ocular hypertension. Sectorial and patchy iris atrophy 
consistent with ischemic damage is characteristic of Herpes Zoster Virus infection. Hypopyon, as well 
as hyphema, may also be seen in more severe cases. The use of aqueous humor Polymerase Chain 
Reaction (PCR) may help identify the Herpes Simplex or Herpes Zoster Virus as the causative agents in 
patients with uveitis of unknown etiology (44).  
According to the Herpetic Eye Disease Study Group, patients with herpetic keratouveitis or uveitis are 
often treated with oral antivirals (acyclovir or valaciclovir) as well as with topical corticosteroids, 
cycloplegics, and intraocular pressure (IOP)-lowering agents (45). Long term use of oral antiviral agents 
is also beneficial in reducing the recurrence rate of stromal disease and uveitis (46).  
2.1.4 Intermediate Uveitis 
Intermediate uveitis is characterized by inflammation that primarily affects the pars plana, vitreous, 
and peripheral retina. Aggregates of inflammatory cells are frequently seen in the inferior vitreous and 
have been termed vitreous snowballs. Similarly, the accumulation of inflammatory cells and debris 
along the pars plana and ora serrata has been called snowbanks. Mild anterior uveitis often coexists, 
and cystoid macular edema is a frequent finding. Common conditions associated with intermediate 










Table VIII. Causes of Intermediate Uveitis (17) 
Sarcoidosis 
Inflammatory Bowel Disease 
Multiple Sclerosis 
Lyme Disease 
Pars Planitis (idiopathic) 
 
 
2.1.5 Posterior Uveitis 
Inflammatory disease limited to the posterior segment of the eye, particularly to the retina and 
choroid, is termed posterior uveitis. For vitreous haze involving obstruction of fundus details by 
vitreous cells and protein exudation, an original scale of clinical photographs (47) illustrating six grades 
of vitreous haze was adopted by the SUN working group (16), but with the extra grade of 0.5+ for trace 
added to the grading scheme. Vitreous haze grading is listed in Table IX. 
 
 
Table IX. Grading Scheme for Vitreous Haze (47) 
Score Description Clinical Findings 
0 Nil None 
0,5+ Trace  
1+ Minimal Posterior pole clearly visible 
2+ Mild Posterior pole details slightly hazy 
3+ Moderate Posterior pole details very hazy 
4+ Marked Posterior pole barely visible 
5+ Severe Fundal details not visible 
 
 





Many diseases cause posterior uveitis, so it is useful to further subdivide these disorders as 
predominantly retinitis or choroiditis and as a focal or multifocal disease. Frequent disorders causing 
focal and multifocal retinitis as well as choroiditis are listed in Table X.  
Table X. Causes of Posterior Uveitis (17) 
Focal Retinitis Multifocal Retinitis Focal Choroiditis Multifocal Choroiditis 
Toxoplasmosis Syphilis Toxocariasis Histoplasmosis 
Onchocerciasis Herpes Virus Tuberculosis Sympathetic Ophthalmia 












 Serpiginous choroidopathy 
 Candidiasis  Birdshot choroidopathy 
   Masquerade syndromes 
 
2.1.5.1 Vogt–Koyanagi–Harada Disease 
Vogt-Koyanagi-Harada (VKH) disease is a severe bilateral granulomatous posterior or panuveitis 
associated with serous retinal detachments, disk edema, and vitritis (48). Systemically, it may be 
associated with tinnitus, hearing loss, vertigo, meningismus, poliosis, and vitiligo, although not all 
patients present with the complete constellation of these extraocular findings. 
The prevalence of VKH varies in different populations in the world, being more common in Asia, Latin 
America, and the Middle East (48).  
VKH seems to be an autoimmune inflammatory condition mediated by CD4+T cells that target 
melanocytes (49). The trigger that induces altered tolerance to melanocytes is unknown but genetic 
susceptibility of patients expressing HLA DRB1*0405, combined with a viral infection, may play a role 
in initiating the autoimmune process (50).  
VKH presents clinically in 4 different phases: prodromal, acute uveitic, convalescent, and chronic 
recurrent. In the prodromal phase, before ocular involvement, clinical manifestations include 
headache (82%), meningismus (55%), fever (18%), nausea (9%), vertigo (9%), orbital pain, and auditory 
disturbances (51).  





Cerebrospinal fluid may show pleocytosis in more than 80% of patients (52). In the acute uveitic phase, 
there is a sudden onset of bilateral granulomatous uveitis with pockets of subretinal fluid and choroidal 
thickening, blurring of vision, and conjunctival injection. Signs also include swelling and hyperemia of 
the optic nerve head and retinal edema (48). The initial posterior uveitis, if untreated, spreads to both 
the vitreous and anterior uvea, although vitritis and anterior uveitis are not necessary for the diagnosis.  
Several weeks to months after the acute uveitic phase, depigmentation of the choroid, vitiligo, and 
poliosis occurs. This convalescent-phase usually lasts for months. Depigmentation of the choroid 
usually results in a “sunset glow” bright orange-red appearance of the fundus. Finally, chronic 
recurrent intraocular inflammation develops in some patients and is characterized by exacerbations of 
granulomatous anterior uveitis that is usually resistant to systemic steroid therapy. This chronic 
recurrent phase usually develops 6 to 9 months after the initial presentation and is marked by 
complications such as RPE proliferation, subretinal fibrosis, subretinal neovascular membranes, 
posterior subcapsular cataract, posterior synechiae, glaucoma, and band keratopathy (53, 54). 
The revised diagnostic criteria for Vogt-Koyanagi-Harada syndrome (55) are listed in Table XI.  
 
Table XI. Revised diagnostic criteria for Vogt-Koyanagi-Harada syndrome (55) 
Complete Vogt-Koyanagi-Harada Syndrome 
1. No history of penetrating ocular trauma or surgery preceding the initial onset of uveitis. 
2. No clinical or laboratory evidence suggestive of other ocular disease entities. 
3. Bilateral ocular involvement [(a) or (b) must be met, depending on stage of disease] 
a) Early manifestations 
1. Diffuse choroiditis, focal areas of subretinal fluid, bullous serous retinal detachments; 
2. If equivocal fundus findings, then the following must be present: 
- Focal areas of delays in choroidal perfusion, multifocal areas of pinpoint leakage, large placoid 
areas of hyperfluorescence, pooling within subretinal fluid, and optic nerve staining; 
- Diffuse choroidal thickening, without evidence of posterior scleritis by ultrasonography. 
b) Late manifestations 
1. History suggestive of prior disease based on findings in the following: 
2. Ocular depigmentation: sunset glow fundus or Sugiura’s sign; 
3. Other signs: nummular chorioretinal depigmented scars, RPE clumping or migration, or recurrent 
or chronic anterior uveitis. 





4. Neurological findings (may have resolved): meningismus, tinnitus, or CSF pleocytosis. 
5. Integumentary findings (not preceding the onset of uveitis): alopecia, poliosis, or vitiligo. 
Incomplete Vogt-Koyanagi-Harada syndrome 
Criteria 1 and 3 and either 4 or 5 must be present. 
Probable Vogt-Koyanagi-Harada syndrome 




Systemic high-dose corticosteroids are the gold standard of initial treatment for VKH. A previous study 
showed that patients receiving systemic corticosteroids at a 200 mg/day dose within 13 days of disease 
onset required a shorter duration of steroid use (10.9 months vs. 24.2 months) with an equal final 
visual acuity (56). Treatment with high-dose systemic steroids has also been shown to be associated 
with a decreased incidence of sunset glow fundus (57). The treatment duration must not be inferior to 
6 months based on studies that show a decrease in further ocular symptoms (58), a decrease in 
recurrence, and an improvement in final visual acuity compared to those treated for shorter periods 
(59). Immunosuppressive agents such as methotrexate, azathioprine, cyclosporine A, mycophenolate 
mofetil, and alkylating agents have been used successfully to treat VKH (60-62) and the International 
Uveitis Study Group, thus, have recommended such immunosuppressive agents as mandatory in the 
treatment of VKH to prevent recurrences (63). 
 
2.1.6 Panuveitis 
The term Panuveitis is reserved for diseases involving all eye segments, typically with a severe sight-
reducing inflammatory response. The common causes of Panuveitis are listed in Table XII. 
 
 
Table XII. Causes of Panuveitis (17) 
Syphilis 








Behçet Disease  
Herpes Virus- Acute Retinal Necrosis 
Infectious Endophthalmitis  
Masquerade syndrome 
2.1.6.1 Behçet Disease  
Behçet disease (BD) is a systemic inflammatory condition of unknown pathogenesis, particularly 
prevalent in the Mediterranean, Middle Eastern, and Far Eastern countries (64). Its histopathologic 
hallmark is an occlusive vasculitis, affecting vessels of various sizes, especially veins (65). It is 
characterized by oral and genital ulcers, ocular inflammatory disease, skin lesions,  vasculitis, and the 
involvement of several other organs (66). The prevalence of ocular involvement in patients with BD is 
variable, ranging from 40 to 70% (67, 68).  
Extraocular manifestations include skin and mucosal manifestations (buccal and genital aphthous 
ulcers, erythema nodosum, pseudofolliculitis, acneiform nodules, superficial migratory 
thrombophlebitis) (65), joint manifestations (arthralgia or arthritis), neurologic manifestations 
(meningitis or meningoencephalitis (69), central venous thrombosis, cerebral arteritis),  vascular 
involvement (deep venous thromboses, superficial thrombophlebitis, arterial aneurysms or arterial 
thromboses) and other manifestations (gastrointestinal tract involvement, renal involvement, cardiac 
involvement, and testicular and epididymal involvement). As there is a lack of a universally recognized 
pathognomonic test, BD diagnosis is primarily based on clinical criteria. Diagnostic Criteria for BD (point 
score system) revised by an International Team Group (70) are listed in Table XIII. 
 
Table XIII. International Criteria for BD - point score system: scoring>= 4 indicates diagnosis. 
Sign/Symptom Points 
Ocular lesions 2 






Genital aphthosis 2 
Oral aphthosis 2 
Skin lesions 1 
Neurological manifestations 1 
Vascular manifestations 1 
Positive pathergy test* 1 
*Pathergy test is optional, and the primary scoring system does not include pathergy testing. 
However, where pathergy testing is conducted, one extra point may be assigned for a positive 
result. 
 
The eye is a frequently affected organ in BD, and uveitis, which is potentially blinding, is one of the 
disease's major manifestations. Other rarer ocular manifestations have been described, including 
episcleritis, scleritis, conjunctival ulcers, keratitis, orbital inflammatory disease, isolated optic neuritis, 
and oculomotor palsies (71-73). 
Uveitis occurs in 60 to 80% of cases, on average 4 years after the onset of the disease's systemic 
manifestations, notably buccal aphthous ulcers (65, 66). It may be the presenting sign in 10 to 20% of 
patients (17). 
The intraocular inflammation associated with BD is typically acute and recurrent. It presents in the 
form of bilateral, symmetric or asymmetric, non-granulomatous panuveitis, associated with retinal 
vasculitis (74).  
Anterior uveitis is most often associated with posterior segment inflammation, although it can be 
isolated in 5 to 10% of cases (71). The appearance of hypopyon reflects particularly severe anterior 
chamber inflammation and is found in 12 to 30% of cases (75).  
Diffuse vitritis of variable intensity is common and may be found in over 85% of cases (76). Occlusive 
or non-occlusive retinal vasculitis is found in more than 90% of patients. It may involve vessels of all 
sizes, mainly veins (73).  Branch retinal vein occlusion occurs in about 6% of cases, while central vein 
occlusions and branch retinal arterial occlusions are rarely seen (77). Moreover, foci of retinitis are 
found in over 50% of cases of ocular BD. They present as superficial retinal infiltrates and are variable 
in number, location, and size (75).  





Ocular complications of BD are frequent and include macular edema, posterior synechiae, cataract, 
optic atrophy, and glaucoma. Diffuse non-cystoid or cystoid macular edema appears in 20 to 75% of 
cases and affects the long-term visual prognosis (71). 
In BD treatment, systemic corticosteroids allow for rapid and effective control of acute ocular 
inflammatory manifestations while awaiting immunosuppressors' full effect. The systematic and early 
use of immunosuppressors in the treatment of BD-associated uveitis has contributed significantly to 
improved visual prognosis while also facilitating discontinuation of steroids (78).  
The most used conventional immuno-suppressants in BD are azathioprine and cyclosporine A. Biologic 
agents like anti-tumor necrosis factor-alpha (anti-TNF-α) are indicated for refractory cases and have 
been increasingly recommended as first-line therapy (79, 80).  
 
2.1.6.2 Acute Retinal Necrosis 
Acute Retinal Necrosis (ARN) is an acute panuveitis secondary to herpetic infection characterized by 
retinal periarteritis progressing to diffuse necrotizing retinitis. The American Uveitis Society defines it 
as having: 1) One or more foci of retinal necrosis with discrete borders located in the peripheral retina; 
2) rapid progression in the absence of antiviral therapy; 3) circumferential spread; 4) evidence of 
occlusive vasculopathy with arterial involvement and 5) a prominent inflammatory reaction in the 
vitreous and anterior chamber (81).  
Serious ocular complications can develop if there is a significant delay in diagnosis and treatment. 
These can cause irreversible visual impairment and include cataract, band keratopathy, glaucoma, 
macular edema, and retinal detachment (82).  Since anti-viral treatment regimens and ocular prognosis 
are different for HSV, VZV, or CMV related infections, it is vital to find the causative agent. PCR analysis 
of intraocular fluids for HSV, VZV, and CMV in this setting has a sensitivity of 80.9–84.0% and a 
specificity of 97.4–100.0% (83).  
 





3. Cytokines in Uveitis 
T cells expressing the surface marker cluster of differentiation 4 (CD4) are known as T helper (Th) cells 
and play essential roles in the pathogenesis of autoimmune diseases, including uveitis (84). Two major 
classes of Th cells were defined (85): Th1 cells, defined by the expression of the transcription factor T-
bet and secretion of interferon-gamma (IFN-ɣ), important in cellular immunity; and Th2 cells, defined 
by the transcription factor GATA binding protein 3 and secretion of interleukin (IL)-4 and IL-5, which 
are essential for humoral immunity (86). 
Th1 cells have been previously implicated in the induction of uveitis in experimental autoimmune 
uveitis (EAU), but several authors have also reported the crucial role of IL-17-producing Th17 cells in 
the genesis of EAU in mice (87). In animal models, this interplay between the Th1 and Th17 responses 
in driving uveitis is complex, as both can drive intraocular inflammation (88).  
Th17 cells develop from naive CD4+T cells in the presence of IL-1β, IL-6, and TGF-β produced by antigen-
presenting cells (APCs). In addition to IL-17A, Th17 cells express IL-22, IL-17F, IL-21, granulocyte-
macrophage colony-stimulating factor (GM-CSF), IL-6, and IFN- ɣ (89). Another T-cell subpopulation 
associated with the development of autoimmune disease is regulatory T cells (Tregs). Treg cells are 
important in maintaining tolerance and preventing autoimmunity and can be identified by their 
expression of the forkhead boxP3 (FOXP3) transcription factor and their ability to produce 
transforming growth factor-beta (TGFβ), IL-10, and IL-35 (90). The role of Treg cells in the pathogenesis 
of non-infectious uveitis (NIU) has been accessed by several studies showing these cells may be 
decreased in patients with active uveitis (91), BD (92), and VKH disease (93). 
Regarding the importance of cytokines in the development of infectious and NIU, previous studies have 
demonstrated elevated plasma levels of several cytokines in active intraocular inflammation. However, 
the inflammatory processes occurring within the eyes and the regulatory role of cytokines in the ocular 
micro-environment are still subject of an ongoing investigation.  
IL-17 pathway cytokines (IL-17A, IL-6, and IL-23) seem to be particularly crucial in NIU's pathogenesis 
and may be useful in a clinical setting either as biomarkers in the diagnosis of specific uveitic disorders 
or as future therapeutic targets.  
 





3.1 The IL-17 Pathway 
Th17 cells are a subset of CD4+ T-cells responsible for the production of interleukin (IL)-17. This T-cell 
subset is responsible for the production of IL-17A, a proinflammatory cytokine involved in several 
autoimmune diseases. Both IL-6 and transforming growth factor (TGF)-β are necessary for Th17 
differentiation and IL-17 expression; they feature complimentary roles since the sole presence of TGF-
β induces T-regulatory (Treg) cell production from CD4+ T-cells (94-96). IL-6 needs to be present in 
order to promote the differentiation of a Th17 cell subset in addition to concurrent Treg cell inhibition 
(97). Although IL-6 and TGF-β have synergistic roles in Th17 cell differentiation, IL-23 is also important 
for Th17 cell expansion and activation (94). On the other end of this spectrum are interferon (IFN)-ɣ 
and IL-27, which play a regulatory role in uveitis induction by suppressing Th17 differentiation (87, 98). 
IL-17 induces the production of other inflammatory cytokines such as IL-6, granulocyte colony-
stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-1, TGF-β, 
and TNF-α; chemokines such as monocyte chemoattractant protein- 1 (MCP-1), cytokine-induced 
neutrophil chemoattractant (KC), and macrophage inflammatory protein-2 (MIP-2); prostaglandin E2; 
intercellular adhesion molecule-1; and matrix metalloproteinases. It is also involved in the recruitment 
of neutrophils, monocytes, and Th1 cells, acting with other inflammatory cytokines to induce 
inflammation in target tissues (99). 
Th1 cells have previously been implicated in the induction of uveitis in experimental autoimmune 
uveitis (EAU), but since then, several authors have reported the crucial role of IL-17-producing Th17 
cells in the genesis of experimental uveitis in mice. They have indicated that treatment with anti-IL-17 
antibodies reduces the induction and severity of uveitis in EAU. Moreover, the degree of intraocular 
inflammation was reduced in IL-17 -/- mice (100), and although both Th1 and Th17 cells are activated 
during EAU (87, 100), it has been proposed that Th17 cells are responsible for retinal inflammation in 
the early stages of uveitis, whereas Th1 expression is increased during the late phases and resolution 
of the disease (87). It has thus been shown that Th1 and Th17 cells are implicated in the genesis of EAU 
and may be synergistic with each other, having definitive functions at different stages of the disease. 
In addition to its obvious proinflammatory role in the induction of EAU, IL-17 expression has also been 
shown to be increased in the human peripheral blood of patients suffering from autoimmune and 
infectious uveitis.  





3.1.1 Experimental Autoimmune Uveitis 
IL-17 is crucial in the development of EAU in mice and other models of experimental autoimmune 
disorders (87, 100). In EAU, the intraocular expression of IL-17 is elevated in mice with uveitis, and it 
promotes the release of inflammatory mediators from ARPE-19 cells, disrupting the retinal pigment 
epithelium barrier function (101).  
There is abundant information regarding the role of Th17 cells and IL-17, its main proinflammatory 
cytokine, in the induction and clinical severity of EAU, although some studies have inconsistently 
determined the specific timing of increased IL-17 expression in this condition. It has been proposed 
that Th17 cells play a more critical role in the early stages of the disease, while more abundant Th1 
cells are evident in the late resolutive phases (87). Conversely, other investigations have shown that 
Th1 cells dominate the early inflammatory stages and that a Th17 response occurs later in the clinical 
course (100). 
The Th1 cytokine, IFN-ɣ, seems to serve a protective role in EAU, suggesting that IL-17 has an important 
inflammatory effect given that IFN-ɣ inhibits IL-17 expression through Th17 suppression. In a study 
addressing the different functions of Th1 and Th17 cells in EAU, IL-17-/- mice showed no difference in 
terms of uveitis severity concerning the early stages of the disease and, after anti-IFN-ɣ and anti-IL-4 
antibody treatment and the concomitant increase in Th17 expression, only the late stages of the 
disease were affected, showing the aforementioned differential response of Th1 and Th17 cell subsets 
during the clinical course of EAU (100). 
In another study concerning the monophasic and relapsing phases of EAU, the authors concluded that 
IFN-ɣ-producing cells might be responsible for initiating recurrence in the relapsing form of EAU. 
Conversely, IL-17-producing cells might be implicated in intraocular inflammation's primary 
mechanisms, thus exhibiting different roles in the monophasic and relapsing forms of the disease 
(102). 
Previous data have also shown that even though a Th1- or Th17-driven response can initiate uveitis in 
an animal model, IL-17 plays a critical role in the induction of EAU; moreover, anti-IL-17 treatment can 
reduce the severity of antigen-induced autoimmune uveitis in mice. The same authors suggested that 
IL-23 may be a key element in the early stages of intraocular inflammation and that its function may 
even surpass the expansion and activation of Th17 cells.  
Furthermore, there seemed to be an exacerbation of the Th17 response and increased disease severity 
with inhibition of the IL-12–IFN-ɣ pathway, reinforcing the previously described regulatory activities of 
these Th1 cytokines in Th17 differentiation (88). 





3.1.2 Non-infectious Uveitis 
Increased IL-17 expression has been proven in several studies measuring its aqueous humour or 
peripheral blood concentration in non-infectious uveitic disorders (Table XIV) and other autoimmune 
diseases as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, systemic lupus 
erythematosus, and psoriasis.  
In a study measuring IL-15, IL-17, IFN-ɣ, TNF-α, and IL-10 levels in the aqueous humour of patients with 
active autoimmune uveitis from different etiologies, including Behçet’s disease, Vogt–Koyanagi–
Harada (VKH) disease, and HLA-B27-associated-uveitis, IL-17 levels were found to be higher in these 
individuals than in control subjects, and these levels were correlated with disease activity (103). 
These results were confirmed by another study that measured IL-17 levels in the peripheral blood of a 
large group of patients with autoimmune uveitis with and without associated systemic disease. 
IL-17 levels were elevated in the serum of uveitis patients compared to controls, and they also served 
as a marker for disease activity (104). Both studies suggest that IL-17 may be used as a possible 
biomarker in autoimmune uveitis. 
 
3.1.3 Infectious Uveitis 
IL-17 has been implicated in the development of toxoplasmic encephalitis in an animal model, and 
since then, there have been studies that have analyzed its role in the induction and maintenance of 
intraocular inflammation caused by an infectious agent. In a previous study, upregulation of IL-17 levels 
in mice chronically infected with Toxoplasma gondii that lacked the IL-27 receptor was observed, and 
the authors suggested a protective role of IL-27 in the inflammation that follows toxoplasmic infection 
(105). Moreover, the inflammatory roles of Th1 and Th17 cytokines and the regulatory roles of IL-10, 
TGF-β, and IL-27 in the immunologic responses following toxoplasmic infection have been reinforced 
in a later study concerning cytokine regulation in T. gondii infection (106). 
 





Table XIV. Increased IL-17 expression in several autoimmune uveitic disorders. 
Systemic or intraocular 
autoimmune disorder 
associated with uveitis 
Main conclusions 
Authors,  
year of publication 
VKH 
Elevated IL-23 serum expression and 
upregulated IL-17 expression in peripheral 
blood mononuclear cells (PBMCs) and CD41+ 
T-cells from VKH patients with active uveitis. 
Chi W. et al., 2007 (107)  
VKH 
Decreased IL-27 expression is associated with 
an elevated IL-17 response in active VKH 
patients. Increased Th17 and IL-17 expression 
in PBMCs from active VKH patients. 
Wang C. et al., 2012 (108) 
VKH 
Treatment with cyclosporine A and 
corticosteroids in VKH disease suppresses IFN-
ɣ and IL-17 expression, which, in turn, 
correlates with disease activity. 
Liu X. et al., 2009 (109)  
VKH 
Increased IL-21 and IL-17 expression in VKH 
patients with chronic or recurrent disease. 
Recombinant IL-21 stimulated IL-17 
production via PBMCs in VKH patients. 
Li F. et al., 2010 (110) 
Birdshot 
retinochoroidopathy (BSRC) 
IL-21, IL-23, and TGF-β may promote 
differentiation and expansion of a chronic 
Th17 cell response in BSRC patients. 
Yang P. et al., 2013 (111) 
BSRC Elevated IL-17 intraocular expression in BSRC. Kuiper J.J. et al., 2011 (112) 
Behçet’s disease (BD) 
Elevated levels of IL-23, IL-17, and IFN-ɣ by 
PBMCs and increased frequencies of IL-17- and 
IFN-ɣ-producing T-cells in BD patients with 
active uveitis. 
Chi W. et al., 2008 (113) 
BD 
Levels of IL-17- and IFN-ɣ-producing CD4+ T-
cells are elevated in the peripheral blood of BD 
patients.  
Shimizu J. et al., 2011 (114)  
BD 
IL-17 expression is elevated in BD patients with 
active uveitis. Anti-TNF-α therapy inhibits 
Th17 cell differentiation and may ameliorate 
intraocular inflammation in BD. 
Sugita S. et al., 2012 (115)  
HLA-B27-associated uveitis 
Elevated IL-17 and IFN-ɣ expression in the 
peripheral blood of HLA-B27-associated 
uveitis patients. The increase in Th17 cells and 
IL-17 may correlate with disease activity. 









One study analyzed the inflammatory cytokine and chemokine levels in the aqueous humour of 
patients with toxoplasmic and viral uveitis. The authors found that IL-17 was upregulated in most 
screened patients with toxoplasmic uveitis when compared to cataract patients without uveitis or with 
those with non-infectious intermediate uveitis. The authors suggested that the presence of elevated 
levels of IL-17 in the intraocular fluids of these patients may be a clue to a possible autoimmune 
mechanism that contributes to ocular inflammation following infection (117). These findings were 
reinforced in a study addressing various cytokine levels in the aqueous humour of patients with uveitis 
from various etiologies – infectious and non-infectious. Patients with toxoplasmic infection and 
subsequent uveitis had significantly increased intraocular levels of IL-17 (118). 
Another recent study highlighted the upregulation of IL-17 expression in patients with acute ocular 
toxoplasmosis and demonstrated a pathogenic role for this cytokine in developing intraocular 
inflammation after T. gondii infection. The authors proposed a possible in vivo therapeutic approach 
for toxoplasmic retinochoroiditis based on the use of local anti-IL-17 antibodies (119).  
 
3.1.4.   IL-17 Induction 
Several studies have shown that TGF-β and IL-6 are essential cytokines in Th17 differentiation and that 
IL-23 and IL-21 may also be crucial in Th17 cell expansion and activation (Table XV). 
 
3.1.5.   IL-17 Suppression 
IFN-ɣ 
Antigen-specific IL-17 production is exacerbated in the absence of IFN-ɣ, increasing the severity of 
uveitis in a murine model of spondyloarthritis. In this model, IL-17 blocking ameliorated intraocular 
inflammation in IFN-ɣ KO mice, attesting to the regulatory function that this cytokine plays in IL-17 
production (120). Moreover, IL-17 expression was increased in the peripheral blood of patients with 
uveitis and scleritis, and also in an EAU model. In this same study, IFN-ɣ upregulated IL-27 expression 
by retinal cells, which, in turn, inhibited Th17 cell proliferation, reducing uveitis severity, and altering 
its clinical course (87). Another study involving an EAU animal model also showed that IFN-ɣ 
ameliorated uveitis through Th1 and Th17 cell inhibition and IL-10 upregulation (121). 





Table XV. Cytokines involved in IL-17 induction. 




year of publication 
TGF-β, IL-6, IL-23 
IL-23 may expand the Th17 cell population, but it cannot 
induce this subset’s differentiation from T-cell 
precursors. TGF-β induces Treg differentiation. The 
association between TGF-β and IL-6 induces Th17 cell 
differentiation.  
Bettelli E. et al., 2006 (96) 
IL-6 IL-6 signaling blockade inhibits Th17 differentiation and 
induces antigen-specific Treg formation in EAU. 
Haruta H. et al., 2011 
(122) 
IL-6 
Early treatment with an anti-IL-6 receptor monoclonal 
antibody ameliorated mice EAU and inhibited Th17 cell 
differentiation.  
Hohki S. et al., 2010 (123)  
IL-6, IL-23 
EAU induction is impaired in IL-6 and IL-23 knockout 
(KO) mice. Blocking of IL-6 and IL-23 ameliorates the 
clinical course of EAU through interference with Th17 
cell differentiation and expansion. The anti-IL-6-
receptor antibody ameliorates EAU by suppressing Th17 
responses. 
Yoshimura T. et al., 2009 
(124) 
IL-21 
EAU induction is impaired in IL-21 KO mice. There is 
decreased IL-17 expression in IL-21 KO mice. IL-21 
signaling blockade inhibits IL-17 upregulation in EAU. 
Wang L. et al., 2011 (125) 
IL-21 IL-21 and its receptor are upregulated in mouse EAU 
with increased IL-17 expression. 
Liu L., et al., 2009 (126) 
IL-23 
IL-23 is upregulated in the peripheral blood of VKH 
patients before and after cataract surgery; it is also 
correlated with intraocular inflammation. 
Jiang S. et al., 2010 (127) 
IL-23 IL-23 and IL-1β induce Th17 expansion and cytokine 
response. 
Wilson N. et al., 2007 
(128) 
IL-23  
IL-23 serum levels are elevated before and after cataract 
surgery in BD patients. IFN-ɣ and IL-27 serum levels are 
elevated after cataract surgery in BD patients. 
Jiang S. et al., 2011 (129) 
IL-23 There is increased IL-17 and IL-23 expression in patients 
with active BD. 
Na S. et al., 2013 (130) 
 
 






IL-27 is a regulatory cytokine capable of inhibiting the differentiation of precursor cells into their Th17 
phenotype. By blocking the production of Th17 cells, this cytokine has been implicated in the 
suppression of experimental autoimmune encephalomyelitis (EAE) and EAU (87, 131). A previous 
investigation addressing the regulatory cytokines, IL-27 and IL-10, in the development of uveitis found 
that mice retinal microglia and ganglion cells constitutively expressed IL-27 and that IL-27 production 
was elevated during uveitis (132).  
IL-27 expression was found to be decreased in BD patients with active uveitis (133), and another study 
demonstrated elevated levels of IL-27 after cataract surgery in VKH patients, indicating that the 
upregulation of this cytokine during the first month following surgery might serve a protective function 
in postoperative inflammation (127). Similar results were found in BD patients after cataract surgery, 
as increased IL-27 serum levels were also evident during the postoperative period. These IL-27 levels 
correlated both with uveitis severity and IFN-ɣ levels (129).  
 
3.1.6.   Therapeutic Targets 
 
Anti-IL-17 
An anti-IL-17 monoclonal antibody was used to treat chronic non-infectious uveitis in patients with 
posterior and anterior segment disease. The treatment featured effects comparable to those of 
historical control patients with chronic non-infectious uveitis treated with infliximab. Specifically, this 
treatment was associated with improvements in visual acuity and intraocular inflammation reduction 
(134). 
Another study conducted of an animal model of spondyloarthritis demonstrated that IL-17 blockade 
reduced intraocular inflammation and peripheral arthritis, although there was suspicion of retinal 
toxicity (120). Treatment of EAU with the anti-IL-17 antibody in rats also showed a reduction in 
intraocular inflammation and of T-cell proliferation during disease onset (135). 
 






Secukinumab, a human monoclonal antibody against IL-17, was used in a Phase III trial to treat chronic 
non-infectious uveitis associated with Behçet’s disease; however, the study’s primary outcome was 
not met (SHIELD study). Some authors have since claimed that the use of secukinumab in chronic 
uveitis has not been correctly assessed to date, since the other two trials enrolling patients with active 
and inactive non-infectious uveitis (not associated with Behçet’s disease) (INSURE and ENDURE) were 
interrupted following the termination of SHIELD. In the SHIELD study, although there was no significant 
difference between the treated patients and controls, there was a reduction in concomitant 
immunosuppressant drugs and a trend toward a reduction in recurrence (136). Since then, other 
studies have shown results that highlighted the importance of IL-17 in the pathological mechanisms 
that lead to uveitis, suggesting that there is still an opportunity for another clinical trial using this or 
other monoclonal antibodies against IL-17 (or the IL-17 receptor) in its treatment.  
 
3.2     IL-6 
IL-6 belongs to a family of cytokines including IL-11, IL-31, ciliary neurotrophic factor (CNTF), 
Cardiotrophin-1 (CT-1), leukemia inhibitory factor (LIF), osteopenia (OPN), and oncostatin M (OSM). It 
functions by binding either a cell surface (IL-6R) or a soluble IL-6 receptor (sIL-6R) (84). The binding of 
IL-6 to its receptor results in the activation of the JAK-STAT (JAK1, JAK2, STAT3) and mitogen-activated 
protein kinase (MAPK) pathways, ultimately leading to the expression of inflammatory cytokines, 
vascular endothelial growth factor (VEGF), and differentiation of naive CD4+T cells into Th17 cells (137).  
In EAU, treatment with an anti-IL-6 receptor antibody or, alternatively, EAU induction in IL-6-deficient 
mice results in dramatically reduced uveitic inflammation (124). Elevated levels of IL-6 have been 
detected in the aqueous humour (AqH) of patients with BD, VKH, sarcoid, idiopathic uveitis, acute 
retinal necrosis (ARN), and HLA-B27-associated uveitis when compared with controls (138-140). The 




Table XVI. Uveitic disorders associated with dysregulated IL-6 or IL-6 receptor (141-143). 
Vogt–Koyanagi–Harada Syndrome 











Tocilizumab (Genentech, South San Francisco, CA, USA) is a monoclonal antibody against soluble and 
membrane-bound IL-6 receptor, and it has been used successfully in case reports in JIA uveitis 
refractory to prior anti-TNF-α therapy (144).  
A previous study involving eleven eyes from seven patients with uveitic CME due to Birdshot 
choroidopathy, JIA, and idiopathic panuveitis showed improved visual acuity and central foveal 
thickness after treatment with tocilizumab (145). The  STOP-Uveitis is a randomized, open-label safety, 
efficacy, and bioactivity clinical trial which evaluated the role of tocilizumab in patients with NIU. This 
study included 37 uveitis patients, and results at 6 months showed that tocilizumab (both 4 and 8 
mg/kg) effectively improved visual acuity and reduced vitreous haze and central macular thickness in 
eyes with posterior NIU (146). 
 
3.3 IL-23 
 IL-23 is a member of the IL-12 superfamily of cytokines. This family includes IL-12, IL-23, IL-27, and IL-
35. The IL-23 receptor is composed of the IL-12Rb1 and IL-23R subunits that signal through tyrosine 
kinase 2(Tyk2), JAK2, STAT3, and STAT4 upon binding IL-23 (147).  
In the context of inflammation, it is primarily produced by antigen-presenting cells such as dendritic 
cells and macrophages, and multiple lines of evidence point to IL-23 as the critical checkpoint used by 
naïve T cells to decide whether to become a homeostatic Th17 or pathogenic Th17 effector cell (88, 
148), which means that in the absence of IL-23, Th17 cells can still develop, but do not become 
pathogenic. 
As for its role in NIU, increased IL-23 levels have been found in the serum and the supernatants of 
peripheral blood mononuclear cells from patients with active VKH and Behçet’s uveitis compared with 
patients with inactive uveitis and normal control subjects (107, 113).  





Table XVII lists uveitic disorders associated with increased IL-23 levels or with single nucleotide 
polymorphisms (SNPs) in the IL-23R gene. 
 
Table XVII. Uveitic disorders associated with increased IL-23 levels or single nucleotide polymorphisms (SNPs) 
in the IL-23R gene. 
Przepiera-Bedzak et al (149) Increased serum levels of IL-23 are associated with an increased 
risk of AAU in patients with spondyloarthropathy. 
Velez et al. (150) Increased IL-23 levels in the vitreous obtained from patients with 
posterior uveitis compared with non-uveitic control subjects. 
Yang and Foster (111) Elevated serum levels of IL-23 in patients with treatment-naïve 
Birdshot Choroidopathy. 
SNPs in the IL-23R gene associated with 
an increased risk of inflammatory 
disease 
In Ankylosing Spondylitis -associated uveitis (151). 
In Sarcoid uveitis (152). 
   AAU: acute anterior uveitis. SNP: single nucleotide polymorphisms. 
 
Ustekinumab, which targets the p40 subunit shared by both IL-23 and IL-12, has been reported to 
effectively control uveitis in patients treated for coexisting severe psoriatic arthritis and plaque 
psoriasis (153) or BD (154). It is currently being studied in a phase II clinical trial to treat patients with 
uveitis - STELARA (clinicaltrials.gov, NCT02911116). In the STELABEC trial, ustekinumab will be tested 
in patients with BD and active posterior or panuveitis (clinicaltrials.gov, NCT02648581). 
3.4 TNF-α 
TNF-α is a member of the tumour necrosis factor family, which includes TNF-α, lymphotoxin, B-cell 
activating factor (BAFF), and a proliferation-inducing ligand (APRIL). TNF Receptor 1 (TNFR-1) is the 
primary receptor for either form, and it is ubiquitously expressed on all cells. TNFR-2 is only expressed 
on immune cells and only responds to membrane-bound TNF-α (84). It has both a membrane-bound 
form and a soluble form. These two forms have distinct actions in chronic infection, and the selective 
targeting of different pathways shows some promise in selectively ameliorating inflammation in 
autoimmunity while preserving antibacterial potency. 





This cytokine is well known as a key mediator of inflammation and plays a crucial role during the early 
phase of a host’s defence against bacterial, viral and parasitic infections, although high systemic levels 
of TNF-α can lead to vascular decompensation and death (155). It is produced by many cell types, 
including macrophages, monocytes, lymphocytes, mast cells, polymorphonuclear leukocytes, 
keratinocytes, astrocytes, microglial cells, intestinal paneth cells, and tumour cells (156). During 
inflammation, TNF-α is produced by Th1 cells in copious amounts as well as by inflammatory 
macrophages, and it acts synergistically with other cytokines, such as IFN-ɣ and IL-17, propagating the 
pro-inflammatory state (157, 158). 
In the EAU model, neutralization of TNF-α suppresses disease (157), and mice deficient in TNFR1 are 
resistant to the development of uveitis (159). Moreover, one previous study analyzed the AqH levels 
of various pro-inflammatory cytokines in patients with NIU, including patients with VKH, BD, and HLA-
B27-associated uveitis, and found an elevated TNF-α expression that correlated significantly with 
disease activity (103). When analyzing patients with idiopathic and HLA-B27-associated anterior 
uveitis, another study also found increased TNF-α levels in the AqH.  However, in patients with 
intermediate uveitis from various causes, only serum TNF-α levels were significantly higher in patients 
with no difference from controls in AqH samples (160).  
TNF-α off-label treatment of NIU patients led to expert-panel recommendations for their use in ocular 
inflammatory disorders (161). In this study, a panel of uveitis experts found good-quality evidence for 
recommending treatment with anti-TNF-α agents (infliximab and adalimumab) for ocular 
manifestations of BD, Juvenile Idiopathic Arthritis, and Spondyloarthropathy-associated or HLA-B27-
associated Uveitis.  
Since then, the VISUAL I and II trials subsequently led to adalimumab approval for treatment of patients 
with NIU (162, 163). The VISUAL I trial showed that in patients with active non-infectious intermediate 
uveitis, posterior uveitis, or panuveitis treated with adalimumab, the median time to treatment failure 
was 24 weeks versus 13 weeks in the placebo group, with a lower risk of uveitic flare or visual 
impairment than placebo.  
Golimumab, a more recent anti-TNF-α agent, also showed success in treating NIU in several 
retrospective case studies (164, 165).  
Etanercept is another well-known anti-TNF-α agent that has been successfully used in several 
autoimmune diseases. However, experts do not recommend its use to treat ocular inflammatory 
disease since there have been reports of the development of sarcoid-like uveitis in patients treated 
with etanercept (161).  






Interferon-gamma (IFN-ɣ) was one of the first recognized cytokines and is known to play well-
characterized roles in immune responses to microbial infection (166). However, it also plays a role in 
the pathogenesis and development of autoimmune disease, and it is now clear that it is more 
accurately described as a modulator of inflammation since it seems to be capable of both pro- and 
anti-inflammatory activities, depending on the biological context. IFN-ɣ is the only characterized Type 
II interferon, as defined by its interaction with the IFN-ɣ receptor (IFNɣR). This receptor consists of a 
complex of two receptor chains, designated IFNɣR1 and IFNɣR2 (167). One of the important 
transcription factors expressed due to IFNɣR signaling is T-bet, the transcriptional regulator necessary 
for inducing and maintaining an interferon-gamma producing, Th1, differentiation state in CD4+ helper 
T cells (166). IFN-ɣ signaling acts to modulate the expression of several cytokines, including IL-12, which 
is a vital component of IFN-ɣ production in both innate and adaptive immune compartments and also 
drives helper cell differentiation towards a Th1 phenotype. Although it has been shown that IFN-ɣ 
decreases T cell differentiation to Th2 and Th17 lineages (168, 169), it is now clear that IFN-ɣ 
production can occur concurrently with IL-17 expression with pathogenic consequences (170, 171). 
In a study measuring pro-inflammatory cytokine levels in the AqH of patients with active uveitis 
associated with BD, VKH, and HLA-B27 (103), patients with BD showed higher intraocular IFN-ɣ levels 
than patients with VKH or HLA-B27-associated disease. These results were consistent with another 
study, which also showed that levels of IFN-ɣ were significantly higher in the AqH of BD patients than 
those found in NIU from other causes (172). The authors concluded that, in BD, there may be a more 
extensive Th1 polarization in the intraocular cytokine environment. Table XVIII lists autoimmune 
diseases with an association with an IFN-ɣ dysregulation. 
 
Table XVIII. Autoimmune Diseases associated with an increased IFN-ɣ expression. 
Multiple Sclerosis (MS) Examination of lymphocytes from MS patients' blood demonstrated 
increased IFN-ɣ production (173). 
Systemic lupus erythematosus (SLE) Deficiency of IFN-ɣ signaling In SLE models ameliorates disease (174). 
Sjögren’s syndrome (SjS) IFN-ɣ deficiency ameliorates disease in SjS mouse models (175). 
 
 






IL-10 is the founding member of the IL-10 cytokine superfamily, which also includes IL-19, IL-20, IL-22, 
IL-24, IL-26, IL-28, and IL-29 (176). It was initially described as a secreted cytokine synthesis inhibitory 
factor (CSIF) produced by Th2 T cell clones, which inhibits the production of several cytokines from Th1 
cells (177). There is a wide variety of cells of the innate and adaptive arms of the immune system 
capable of IL-10 expression, including macrophages, monocytes, dendritic cells (DCs), mast cells, 
eosinophils, neutrophils, natural killer (NK) cells, CD4 + and CD8 + T cells, and B cells (178). The IL-10 
receptor (IL-10R) is a tetramer consisting of two α and two β subunits, where α are responsible for 
binding IL-10, and β is part of signal transduction. Like many other cytokines, receptor signaling is 
mediated by the JAK-STAT pathway, in this case, through JAK1, STAT1, and STAT3 (179).  
Consequently, it can inhibit the production of proinflammatory cytokines, antigen presentation, and 
cell proliferation (180, 181). IL-10 performs these regulatory functions by binding to a specific cell 
surface receptor (IL-10R) that is made of two chains, IL-10R1 and IL-10R2.  
The binding of IL-10 to IL-10R1 leads to conformational changes in IL-10 that allows its association with 
the IL-10R2 and the generation of IL-10/IL-10R complexes.  
These complexes can suppress immune responses by multiple mechanisms, but inhibiting nuclear 
translocation of the NF-κb and its DNA-binding activity is considered the main one (182). IL-10 also 
inhibits major histocompatibility complex class II expression, limiting co-stimulation and reducing 
proinflammatory cytokine production by antigen-presenting cells (APC), particularly dendritic cells and 
macrophages (183). 
Different studies have reported different IL-10 levels in the AqH and sera of patients with uveitic 
disorders, including non-infectious and infectious uveitis. Animal studies demonstrate the protective 
role of local IL-10 in uveitis, both in EAU and endotoxin-induced uveitis (EIU) (184-186). In patients 
with uveitis from various causes, elevated intraocular IL-10 levels have been identified (160, 187) and 
are attributed to the presence of regulatory mechanisms activated along with inflammation. The 
presence of consistently elevated levels of IL-10 in the AqH of IU patients, particularly in viral uveitis 
(118, 188-190), may be related to its ability to potently suppress the cellular immune response and 
increase the host susceptibility to infection. Increased IL-10 is thought to play an essential part in 
persistent infections caused by viruses, bacteria, and parasites, and it is known that Cytomegalovirus 
(CMV) and Epstein Barr virus (EBV) can induce IL-10 synthesis and encode their own IL-10 homologs 
(191-193). 





The evaluation of intraocular IL-10 levels can be particularly helpful when there is a suspicion of 
Primary Intraocular Lymphoma. In these cases, an elevated IL-10/IL-6 ratio strongly suggests this 
diagnosis (194). Table XIX lists uveitic diseases that have been associated with an IL-10 dysregulation. 
 
3.7 TGF-β 
TGF-β1 is part of the TGF-β superfamily members, collectively coded by 33 different genes in mammals 
(195). The family comprises the three TGF-β isoforms TGF-β1, TGF-β2, and TGF-β3; activins (Act); bone 
morphogenetic proteins (BMPs) and/or growth differentiation factors (GDFs) (196), which are all 
dimers. TGF-β1 is a homeostatic factor that keeps the immune system in balance and orchestrates the 
complex tissue repair processes following injury or infection in all organs (197). 
 




Idiopathic Uveitis (198) Low IL-10 levels in the AqH of patients. 
Fuchs’ Uveitis Syndrome (199) High IL-10 levels in the AqH of patients. 
VKH, BD, HLA-B27-associated (103) 
Increased IL-10 levels in the AqH of patients and a 
positive correlation with disease activity. 
Infectious 
Uveitis (IU) 
ARN and Toxoplasma Chorioretinitis 
(188) 
High IL-10 levels in patients with uveitis. 
Laboratory confirmed intraocular 
infection (not specified)(190) 
IU Patients had higher levels of IL-10 than NIU 
patients. 
Herpetic Uveitis (189) 
Significantly increased IL-10 levels in the AqH of IU 
patients compared with those with NIU. 
Toxoplasmosis and viral uveitis (HSV, 
HZV, and CMV) (118) 
Increased IL-10 levels in viral uveitis, whereas IL-17A 
levels were augmented in toxoplasmic uveitis. 
ARN: Acute Retinal Necrosis; AqH: Aqueous humour; HSV: Herpes Simplex Virus; HZV: Herpes Zoster Virus; 
CMV: Cytomegalovirus.  
 





It is involved in about every aspect of the immune system and in regulating inflammation, either by 
inducing direct actions or by setting baseline states in immune cells that determine the reaction to 
other signaling events (200). It has a role in the development and survival of the T cell population in 
the thymus, such as CD8+ T cells, CD4+/CD25+/FoxP3+ T regulatory cells (Treg), intraepithelial 
lymphocytes, and invariant natural killer T cells. It becomes critical in suppressing autoreactive T cells 
that escape the thymus's negative selection process and manage to circulate to the periphery (201).  
TGF-β is also vital for maintaining an inhibitory ocular microenvironment. Regarding its isoforms, there 
is very little to no detection of the other isoforms, other than TGF-β2, in healthy AqH (202). 
Macrophages treated with TGF-β2 express the characteristics of the aqueous humor-treated 
macrophages that mediate ACAID (Figure 2), (203). These TGF-β2 treated macrophages increase their 
F4/80 surface expression while reducing the expression of co-receptors for T cell activation (204, 205) 
and expressing TGF-β1 (206).  
Moreover, TGF-β2 triggers the expression of FOXP3 in CD4+T cells and subsequently converts them to 
FOXP3+T regulatory cells (Tregs) (207, 208). A recent study showed an inhibitory role of TGF- β2 in 
EAU, given that treatment with TGF-β2 during the early stages of intraocular inflammation completely 
suppressed the immune response by inhibiting CD4+T cell proliferation and generating Tregs (209). 
The authors suggest that recombinant TGF-β2 could be a successful therapeutic agent for local 
treatment of human idiopathic anterior uveitis. 
 
4. Regulatory T cells 
Regulatory T cells (Tregs) are a cluster of CD4+T cells, which can be classified into two main types: 
thymus-derived or “natural” Treg cells and peripheral or “adaptive” Treg cells  (210). So far, no distinct 
functional differences have been conclusively demonstrated between thymus-derived and peripheral 
Tregs, suggesting that the mechanistic repertoire of Treg function is specified by lineage and not mode 
of induction (211). Nonetheless, typically natural Tregs act mainly by contact with target cells through 
their surface markers, and peripheral Tregs act mostly by cytokine production. They can be mobilized 
in a variety of immune responses - including allergy, autoimmunity, inflammation, and tumoral 
immunity (212). 





Natural Tregs are characterized as expressing both the CD4 T-cell co-receptor and CD25, a component 
of the IL-2 receptor. IL-2 and its CD25 receptor are vital for developing and maintaining a Treg pool 
(213). Tregs are, thus, phenotypically characterized as CD4+ CD25+. Moreover, they also express 
intracellularly a specific marker called FOXP3. 
 Peripheral Tregs are characterized by TGF-β and IL-10 production and play an essential role in 
maintaining T cell homeostasis and self-tolerance (214, 215), particularly in peripheral immune 
tolerance (216).   
FOXP3, also known as scurfin, is a protein involved in immune system responses, and it serves as a 
critical factor for the thymic development of CD4+CD25+ regulatory natural T-cell (217). It is critically 
important for the development and function of thymic Tregs (218), and it keeps the cells on the right 
developmental track toward a suppressive phenotype, being considered a prerequisite for stabilizing 
the Treg lineage (219). Furthermore, loss of FOXP3 expression impairs the suppressive activity of Tregs 
(217).  It has been extensively used as a marker for CD4+CD25+ Tregs, distinguishing them from 
activated CD4+CD25–T cells. 
However, FOXP3 detection requires intracellular staining, which limited the applicability of this 
phenotype to cell research. Later, a negative correlation between the IL-7 receptor (CD127) expression 
and FOXP3 expression was found, further characterizing Tregs as low CD127-expressing cells (220).  
FOXP3+CD4+ non-Tregs are characterized by the absence of cell surface expression of CD39 and IFN-
γ, IL-2, and IL-17 expression (221). CD39 is an ectonucleotidase that cleaves ATP to form AMP, which 
is then be cleaved by CD73 to form adenosine. Since extracellular ATP has a known proinflammatory 
effect, its cleavage to AMP and subsequent adenosine formation will induce a suppressive immune 
response (222).  
CD39 has been reported on the surface of naive human Tregs, and it has been confirmed that it is 
predominantly expressed on CD4+ FOXP3+ T cells with an expression level that is proportional to 
FOXP3 (223). There is a growing body of evidence implicating CD39 expression as vital for natural Tregs' 
suppressive function (223, 224). A study analyzing Treg CD39 expression in patients with inflammatory 
bowel disease (IBD) found that although the total numbers of circulating FOXP3+ Treg cells did not 
differ between controls and patients with active IBD, there was significantly lower CD39 expression by 
Treg cells in active IBD (225). In patients with relapsing-remitting multiple sclerosis (MS), CD39+ Tregs 
isolated from patients have been shown to have impaired suppressive activity over the Th17 response 
(221), and RA patients with higher frequencies of circulating CD39+ Tregs were associated with a 
positive clinical response to MTX (226). 





Moreover, some studies suggest that the expression of CD39 by human Tregs (222) is restricted to a 
subset of T regulatory effector memory cells (221) and that these cells are particularly capable of 
suppressing IL-17 production.  
CD39 expression is intimately associated with CD4+CD25+FOXP3+ signatures and the acquisition of a 
memory (CD45RO+/RA-) phenotype. Furthermore, FOXP3 appears to drive CD39 expression as 
evidenced by retroviral transduction of CD4+CD25− T cells with FOXP3 (222). Other studies have also 
demonstrated amplification of the CD39 gene by FOXP3 (219). These findings suggested that the CD39 
surface marker can be successfully used for routine isolation of functionally active human Tregs. 
Recent studies have succeeded in dividing human Tregs into more homogenous subsets based on cell-
surface marker expression. Dividing human Tregs into distinct subsets has been fruitful for improving 
our understanding of basic human Treg biology and will likely be critical to future studies of the role of 
human Tregs in autoimmune disease.  
The most common approach to defining human Treg subsets is based on combining CD25 and CD127 
expression with the expression of the classic markers for memory (CD45RO) and naïve (CD45RA) 
conventional T cells (227, 228).  
This further isolated two suppressive FOXP3+Treg populations that are distinct in phenotype and 
function: CD25+CD127lowCD45RA+FOXP3+ (naïve Tregs) and CD25highCD127lowCD45RO+ FOXP3+ 
(memory Tregs).  
Memory Tregs express the highest levels of CD25, FOXP3, and other markers of activated T cells, exhibit 
the most substantial suppressive capacities, exhibit hyporesponsiveness and undergo apoptosis in 
response to TCR stimulation (227, 229, 230).  
Naïve Tregs express CD25 and FOXP3 at lower levels, exhibit weaker suppression, substantial 
proliferation, and resistance to apoptosis in response to TCR stimulation (227, 228, 230). Compared to 
naïve Tregs, human memory Tregs are more activated and more fully differentiated in their ability to 
perform strong suppression (230). A prospective study of Treg phenotype from human infants has 
provided considerable evidence to support this model by demonstrating naïve Treg conversion into 
memory Tregs starting around 18 months (231).   





Memory Tregs cells seam to maintain long-lived tolerance to self-antigens and have been identified on 
mouse models in which self-antigens' expression could be turned on and off, showing the persistence 
of antigen-specific Treg cells even after antigen elimination (232). Human T-cells express the RO 
isoform of CD45 in the thymus and convert to CD45RA upon migration to peripheral tissues, switching 
back to CD45RO after antigen recognition and TCR stimulation (233). Therefore, circulating memory T-
cells are phenotypically characterized as CD45RA-/CD45RO+.  
Miyara et al. demonstrated that human FOXP3+Tregs could be further divided into three 
phenotypically distinct subpopulations: CD45RA+FOXP3(lo) resting Treg cells, CD45RA-FOXP3(hi) 
activated Treg cells, both demonstrating in vitro suppressive capacity, and CD45RA-FOXP3(lo) non-
suppressive T cells (227). However, the role and characterization of memory Tregs in the 
physiopathology of autoimmune disease and the importance of CD39 expression on memory Tregs 
need to be further elucidated.  
In Type 1 diabetes (T1D) patients, a study by Jin et al. found that patients had higher memory Tregs 
percentages than controls but showed impaired suppression with low FOXP3 and CD39 expression 
(234). These study results are in accordance with a previous study, also involving children with T1D, in 
which a lower expression of CD39 within Tregs was also found in patients (235).  
The authors concluded that an impaired suppressive function of Tregs in T1D patients was due to a 
reduced CD39 expression on their memory subpopulation. 
4.1 Tregs in Autoimmune Diseases 
Several studies have analyzed circulating regulatory T cell frequencies in autoimmune diseases like 
Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory 
Bowel Disease (IBD), Autoimmune Thyroid Disease (ATD), and T1D. However, there has been some 
discrepancy in results since there are reports documenting decreased, normal, and increased 
circulating Treg frequencies relative to health.  
The reasons behind the reported inconsistencies are not fully understood. One potential explanation 
for the observed discrepancies is a lack of standardization between studies due to the absence of a 
uniformly recognized marker, which reliably defines a homogenous human Treg population (236). 
Table XX lists some of the autoimmune disorders associated with an altered circulating Treg frequency. 
 





4.2     Tregs in Non-Infectious Uveitis 
In NIU, a decrease in Treg frequency has been previously demonstrated (91) and has been associated 
with various causes of NIU, which include BD (92), VKH (93), and HLA-B27-associated anterior uveitis 
(237). Table XXI lists some of the uveitic disorders associated with a decrease in circulating Treg 
frequency or dysregulation. However, other studies failed to show this disease-associated reduction 
(238, 239), with one study reporting significant reductions in FOXP3+Treg levels in both controls and 
uveitis patients after in vitro dexamethasone treatment (238).  
The Th17/Treg ratio has also been studied in NIU patients showing an elevation during active 
intraocular inflammation in HLA-B27-associated uveitis (237) and a positive correlation with disease 
activity score. Such observations suggest that both the elevation of Th17 cells and the reduction of the 
Treg subset may contribute to disease activation and progression. However, this may not be the case 
for all the uveitic conditions causing NIU since a recent study involving Birdshot Chorioretinopathy 
(BSCR) patients showed that the proportion of CD4+CD25hiCD127lowcells was higher in treated and 
untreated BSCR patients than in controls. Additionally, Th17 and CD4+CD25hiCD127lowcells levels were 
not significantly different between treated and untreated patients (240).  
 
Table XX. Autoimmune diseases associated with an altered circulating Treg frequency. 
SLE 
Decreased CD4+CD25+ T cell frequency. (241)  
Normal frequency of the CD4+CD25hi subset in active disease. (242)  
Levels of circulating Tregs cells are reduced during flares. (243)  
MS 
Decrease in the relative frequency and suppressive function of CD4+CD25+CD127lowFoxP3+CD39+ 
Treg cells. (221)  
Decreased FOXP3 levels in Tregs may contribute to MS. (244)  
The frequency of Tregs in the peripheral blood did not differ between MS patients and healthy 
donors. (245)  
RA 
The frequency of peripheral blood Treg cells in patients with RA was significantly low compared 
with that of healthy controls. (246)  
Decrease in the CD4+CD25high regulatory T-cell population in the peripheral blood of individuals 
with early active RA prior to disease-modifying treatment. (247)  






No differences were found in the frequency of Tregs as a percentage of CD4+ cells between ATD 
patients and controls but patient´s Tregs were less capable of inhibiting the proliferation of T 
effector cells. (248)  
The proportion of Treg cells and the transcription factor forkhead box P3 (FOXP3) mRNA 
expression is decreased in Graves’ Disease patients when compared with healthy subjects. (249)  
IBD 
Decrease of CD4+FOXP3+ Treg cells in peripheral blood of patients and an accumulation of Treg 
cells in inflamed mucosa. (250)  
A decrease in Tregs and an increase in Th17 cells were observed in the peripheral blood of IBD 
patients. (251)  
CD4+CD25high and FOXP3+ Treg cells are increased during remission but decreased during active 
disease. (252)  
T1D 
In contrast to previous studies of T1D patients, similar frequencies of CD4+CD25+ T-cells were 
observed in healthy control subjects and patients of similar age. There was no difference 
between T1D subjects of recent-onset versus those with established disease in terms of their 
CD4+CD25+ or T-cell frequency. (253)  
The percentages of CD4+CD25+ and CD4+CD25+Foxp3+ cells both in total lymphocytes and in 
CD4+ lymphocytes were significantly decreased in patients when compared to controls. (254)  
SLE- Systemic Lupus Erythematosus; MS- Multiple Sclerosis; RA- Rheumatoid Arthritis; ATD- Autoimmune 
Thyroid Disease; IBD- Inflammatory Bowel Disease; T1D- Type 1 Diabetes. 
 
Table XXI. Uveitic disorders associated with a decrease in circulating Treg frequency or dysregulation 
NIU- Non-Infectious Uveitis; BD- Behçet Disease; VKH- Vogt-Koyanagi-Harada; BSCR- Birdshot Chorioretinopathy; AAU- 
acute anterior uveitis. 
NIU 
20 patients with intermediate 
uveitis, posterior uveitis, and 
panuveitis. 
T-regulatory cells are reduced in patients with active 
compared with inactive disease. (91)   
BD 
19 BD patients with ocular 
complications. 
Decreased percentages of Treg cells may be a predictive 
marker of ocular attack in BD patients. (255)   
16 BD patients with refractory 
uveitis. 
The percentage of Foxp3+ cells among CD4+ T cells was 
significantly decreased in patients with active uveitis 
compared with patients with inactive uveitis in the 
remission stage. (92)  
VKH 30 patients with active VKH. 
A significantly decreased frequency and diminished 
function of CD4+CD25high Treg cells are associated with 
active uveitis in patients with VKH syndrome. (93)  
BSCR 
12 patients, HLA-A29+ and 
with a history of untreated 
disease. 
The percentage of CD4+CD25+Foxp3+ Tregs was 
significantly lower in BSCR patients compared with 
controls. (256)  
HLA-B27-
associated 
20 patients with HLA-B27-
associated AAU. 
Increase in circulating Th17 cells and a 
significant decrease of Treg cells in patients 
compared to controls. (237)  





The heterogeneity of the different conditions causing NIU and the different strategies used to 
characterize Tregs may contribute to conflicting results and delay Tregs' possible use as biomarkers or 
even as therapeutic targets in NIU. Treg therapy in preclinical and clinical studies involves two main 
approaches: the systemic autologous antigen-specific and the local polyclonal strategies (257).  
 
4.3 Therapeutic strategies  
The use of T cells for treating diseases has emerged as an attractive target for new therapeutic 
strategies of translational medicine. In the last few years, there have been considerable efforts to 
understand the generation, activation, and mechanisms of action of Tregs, leading to the development 
of tools and treatment modalities. 
 
Systemic autologous antigen-specific strategy 
Only a few clinical studies in humans have been completed. They have been performed mostly in the 
transplantation setting and in several autoimmune diseases, such as Crohn’s disease (CD) (258). In 20 
patients with refractory CD, administration of antigen-specific Tregs was well tolerated and had dose-
related efficacy based on a reduction in Crohn's Disease Activity Index in 40% of patients. In this study, 
ovalbumin-specific Treg cells (ova-Tregs) were isolated from patients' peripheral blood mononuclear 
cells, exposed to ovalbumin, and administrated intravenously. After intravenous administration, 
ovalbumin-specific type 1 Treg cells were specifically activated by ovalbumin in the gut of patients with 
Crohn’s disease and displayed a bystander regulatory activity witnessed by the decrease of the disease 
symptoms in responder patients.  
A previous study using Col-Treg cells, produced from collagen II-specific T cell receptor transgenic mice, 
demonstrated that these cells were able to display several modes of actions allowing the dampening 
of inflammation in vitro, such as anti-inflammatory cytokine production (IL-10 and IL-13), myeloid cell 
cytolysis (through Granzyme B production), and ATP hydrolysis (through CD39 expression) (259). In 
vivo data obtained in a mice model of EAU demonstrated the reduction of several uveitis features, 
such as vasculitis and vitritis, after intravenous administration of Col-Treg cells.  
 





Local administration of ex vivo-activated polyclonal regulatory T cells  
A different treatment strategy involves injecting pre-activated polyclonal Treg cells directly into the 
site of inflammation. In uveitis, this approach would be dependent on intravitreal injections of 
activated Tregs. In the eye, a therapeutic effect of Treg cells might be obtained with small cell numbers, 
without the requirement for in vitro Treg expansion. One study showed uveitis suppression after 
preactivated Polyclonal Treg intravitreal injection (260).  
Disease control by these Treg cells was associated with an increase of IL-10 production and decreased 
reactive oxygen species produced by immune cell infiltrates. Based on these preclinical data, the 
UVEREG phase I/II clinical trial is currently assessing the safety of ex vivo-activated polyclonal Treg 
















1. General Aims 
1) To characterize Regulatory T cell frequency, subsets as well as their respective CD39 expression 
in patients with Non-Infectious Uveitis; 
2) To characterize cytokine expression in patients with Non-Infectious and Infectious Uveitis. 
 
2. Specific Aims 
1) To analyze the peripheral Regulatory T cell subpopulations and respective CD39 expression, as 
well as inflammatory and anti-inflammatory cytokines in a group of patients with active NIU 
and compare them with normal controls. 
 
2) To compare the peripheral Regulatory T cell subpopulations and respective CD39 expression, 
as well as inflammatory and anti-inflammatory cytokines, before and after treatment of NIU. 
 
3) To analyze the local and peripheral inflammatory and anti-inflammatory cytokines in a group 


















This study was performed in accordance with the Declaration of Helsinki. All patients and controls were 
recruited from the Ophthalmology Department of Egas Moniz Hospital, West Lisbon Hospital Center, 
between October 2014 and December 2016. The study protocol was approved by the Ethics 
Committee of Egas Moniz Hospital, West Lisbon Hospital Center, and by the Ethics Committee of NOVA 
Medical School. Informed consent was obtained from each patient.   
All patients were over 18 years old and were diagnosed with active NIU at the time of inclusion. The 
diagnosis of active NIU followed the clinical criteria based on inflammatory cell reaction in the anterior 
chamber or vitreous as per standardization of uveitis nomenclature (SUN) and National Eye Institute 
(NEI) grading systems (16, 261). Active chorioretinal lesions and vasculitis were evaluated by indirect 
ophthalmoscopy, fundus autofluorescence, and fluorescein angiography. Any mentioned 
inflammatory sign (i.e., anterior chamber cell ≥0.5+, vitreous cells ≥0.5+, active retinal vasculitis, or 
active chorioretinal lesions) was enough to be eligible. 
VKH disease was diagnosed according to the criteria established at the International Workshop on VKH 
disease (55). HLA-B27-associated AAU was diagnosed by HLA typing of peripheral blood cells and 
typical ocular manifestations (262). BD was diagnosed according to the criteria of the International 
Team Group for the Revision of the International Criteria for BD (263). Tubulointerstitial nephritis and 
uveitis syndrome (TINU) was diagnosed based on the reports of Mandeville et al. (264) and Mackensen 
and Billing (265). Patients presenting with active uveitis from a presumed viral/herpetic etiology were 
included in the infectious uveitis group.  
The patient´s blood samples were collected at the time of diagnosis and at least three months after 
treatment. For patients to be included, uveitis resolution had to be obtained after treatment. For the 
uveitis to be considered inactive, no inflammatory signs could be present (i.e., no anterior chamber 
cell reaction, no vitreous cells, and no active retinal vasculitis or chorioretinal lesions). 
Data collected from patients included demographic information, diagnosis, anatomical location 
according to the SUN criteria (16), and disease activity. The control group included sex- and age-
matched healthy subjects without any history of autoimmune disease or intraocular inflammation.  





Patients presenting with active uveitis from a presumed viral/herpetic etiology were included in the 
Infectious Uveitis group. At the time of sampling, all patients had active disease, and both blood and 
AqH samples were collected at presentation. Intraocular samples were also examined for the presence 
of cytomegalovirus (CMV), herpes simplex virus (HSV)-1 and 2, and varicella-zoster virus (VZV) by real-
time polymerase chain reaction (PCR) analysis as previously described (266).  
Controls were selected among healthy subjects undergoing cataract or refractive surgery, with no 
known history of intraocular inflammation. 
 
2. Detecting T lymphocyte subpopulations by flow cytometry 
 
Peripheral blood (10 mL ) was collected from patients and controls using Ethylene Diamine Tetra-acetic 
Acid (EDTA) tubes. Multiparametric flow cytometry was performed. 100 microliters (μL) of all samples 
were labeled with the antibody combinations in one tube as follows: CD197-BV241 (Clone 150503, 
BDBiosciences™), CD45-V500 (Clone 2D1, BDBiosciences™ ), CD45RA-FITC (Clone HI100, Biolegend™), 
CD25-PE (Clone M-A251, Biolegend™), CD4-PerCP-Cy5.5 (Clone SK3, BDBiosciences™), CD39-PE-Cy7 
(Clone A1, Biolegend™), CD127-APC (Clone A019D5, Biolegend™), CD3-APC-H7 (Clone SK7, 
BDBiosciences™).  
All incubations were performed at room temperature in the dark. First, cells were incubated with 
appropriately titrated, fluorescently labeled antibodies for 15 minutes. Cell suspensions were then 
lysed and fixed with 2mL of BD FacsLyse (BD Biosciences) for ten minutes and centrifuged for 300 
seconds at 1200 x g. The supernatant was aspirated and discarded. The cells were then washed with 2 
mL of CellWash (BD Biosciences) and resuspended with 500 μL of BD FacsFlow (BD Biosciences) before 
the acquisition. More than 400,000 events were typically acquired on a 3-laser BD FACSCanto II flow 
cytometer (BD Biosciences) with BD FacsDiva software for each measurement. Set up and validation 
of the method included tube replicates in some samples. 
The flow cytometry data were analyzed using Infinicyt 2.0 software (Cytognos, Spain). A unique 
template and strategy of analysis were created and applied to all the files to improve reproducibility.  





The analysis of the CD4+T-cells included the following subpopulations: Tregs 
(CD3+CD4+CD25hiCD127lowcells), naïve CD4+ T-cells (CD3+CD4+CD45RA+CD197+), memory CD4+ T-
cells (CD3+CD4+CD45RA-CD197+/-) and effector CD4+ T-cells (CD3+CD4+CD45RA+CD197-). Tregs were 
defined as CD3+CD4+CD25hiCD127lowcells. Naïve and memory Treg subsets were also identified as 
well as their respective CD39 expression according to the above described phenotypes (Fig. 4). 
Fig. 4 - A. CD4+CD3+ auxiliary T-cells in red, CD4+CD3+CD25hiCD127low Treg population in violet. B. Naïve 
(CD45RA+CD197+) CD4+ T-cells in purple, memory (CD45RA-CD197+/-) CD4+ T-cells in brown, and effector 
(CD45RA+CD197-) CD4+ T-cells in green. The Treg population in gold is mostly concentrated in the memory 
subset. C. The CD39+ Treg cell subset in turquoise overlaying the previously displayed subsets. 
 
Cells were assessed in absolute counts and percentage values (CD4+-T cells as a percentage of total 
CD3+-T cells; naïve, memory, effector, and Treg subsets as a percentage of total CD4+-T cells; and naïve 
and memory Tregs, as a percentage of total Tregs). 
For each sample, the absolute cell counts were calculated by multiplying each population's fraction by 
the total white blood cell count derived from the complete blood count. 
 
3. Quantification of serum cytokine levels by multiplexed flow cytometry 
A multiplex bead-based immunoassay (BD CBA Flex Set, BD Biosciences) was used to determine the 
serum and AqH levels of TNF-α, IFN-ɣ, IL17A, and IL10. A similar single-plex bead-based immunoassay 
was used for TGF-β.  
B C A 





The protocol was performed following the instructions of the manufacturer. In brief, standards and 
serum samples were incubated with specific capture beads for one hour at room temperature. After 
adding the detection reagent, the mixtures were incubated for two hours at room temperature in the 
dark. After a final wash, beads were acquired in a BD FACS Canto II (BD Biosciences), previously set up 
for the BD CBA Flex Set. For each cytokine, a minimum of 300 beads was acquired per sample. The 
FCAP Array Software (BD Biosciences) was used for data analysis. Standard curves covered a 0–2,500 
pg/mL concentration range and the minimum detection levels were: 0.13 pg/mL for IL10; 0.3 pg/mL 
for IL17; 1.8 pg/mL for IFN-γ and 0.7 pg/mL for TNF-α. 
For TGF-β, analyzed separately, samples were previously activated with the Sample Activation Kit 1 
(R&D, Minneapolis, MN, USA) according to the recommended procedure. After activation, samples 
were incubated with capture beads for two hours, washed, and incubated with a detection reagent. 
Acquisition and analysis were performed as described above. For TGF-β, standard curves covered a 0–
10,000 pg/mL concentration range, and the minimum detection level was 14.9 pg/mL. 
 
 
4. Statistical analysis  
Categorical variables were expressed as absolute frequencies and percentages and analyzed using 
Fisher’s exact test. The normality of distributions was assessed using the D’Agostino and Pearson test. 
Normally distributed data are presented as mean (SD) and non-normally distributed data as median 
(IQR).  Two independent groups were compared using the Mann-Whitney U test, and paired data were 
compared using the Wilcoxon signed-rank test. A P-value of <0,05 indicated the presence of a 
statistically significant difference. The Spearman´s rank correlation test was used to analyze 
correlations between cytokine levels and T-lymphocyte subsets. Data were analyzed using GraphPad 
Prism, version 6.01 for Windows (GraphPad Software, La Jolla, California). 






1. Regulatory T cells and IL-17A levels in Non-infectious Uveitis 
1.1. Clinical characterization  
A total of 29 patients with a clinical diagnosis of active non-infectious uveitis were recruited. Regarding 
the different diagnoses, 3 had an idiopathic disease, 20 had HLA-B27-associated uveitis, 3 had BD, 2 
had VKH disease, and 1 had TINU. Patients with HLA-B27-associated disease were also analyzed 
separately. 
Patient demographics are listed in Table XXII. NIU patients included 13 males and 16 females, with an 
average age of 47 (range, 24-80 years old). At the time of sampling, all patients had active disease, and 
blood samples were collected at presentation. This was the first episode of symptomatic intraocular 
inflammation for all the patients included, and none had received previous topical or systemic 
treatment for ocular and/or extraocular symptoms. 
 




















aUnpaired t test; bFisher’s exact test. 
 
1.2. Characterization of lymphocyte subsets in NIU patients and controls 
In this study, we characterized several circulating T cell subsets, but no significant differences were 
found between patients and controls for any of the studied CD4 subpopulations, including the 
regulatory subsets and respective CD39 expression (Table XXIII). 
Considering the distinct etiologies present in the NIU group, we further isolated HLA-B27+ patients and 
compared it both to healthy controls and other causes of NIU. However, again, no differences were 
found in both comparisons for any of the studied T-cell subsets. 
 
 





Table XXIII. Characterization of lymphocyte subsets and serum cytokine levels in NIU patients and controls 
          Group's comparisons 




























Cells/µL, median (IQR)                 
     Total Tregs 69 (35) 70 (36) 67 (32) 57 (40) 0,107 0,738 0,121 0,220 
     Naive Tregs 16 (14) 16 (22) 18 (11) 14 (16) 0,271 0,416 0,593 0,198 
     CD39+ naive Tregs 2 (2) 2 (1) 2 (2) 2 (1) 0,908 0,902 0,819 1,000 
     Memory Tregs 50 (18) 52 (24) 46 (15) 33 (33) 0,112 0,210 0,053 0,384 
     CD39+ memory Tregs 29 (14) 32 (13) 27 (21) 26 (20) 0,380 0,089 0,127 0,930 
Percentages, median (IQR)                 
(Within CD4+ T cells)                 








7,43 (1,22) 0,329 0,650 0,474 0,358 







1,81 (0,98) 0,691 0,101 0,503 0,220 
     CD39+ naive Tregs (within 







0,21 (0,18) 0,429 0,905 0,547 0,464 






5,27 (1,18) 0,664 0,812 0,578 0,838 
     CD39+ memory Tregs (within 







3,23 (1,40) 0,646 0,288 0,274 0,838 
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0,807 0,083 0,235 0,545 









0,695 0,068 0,185 0,626 









0,695 0,068 0,185 0,626 









0,788 0,062 0,217 0,545 
Serum Cytokine Levels (n=28) (n=12)             







































1962 (671) 0,650 0,397 0,943 0,446 
NIU, Non-infectious Uveitis; IQR, interquartile range. Results are presented as medians and interquartile range, 
median (IQR). * Mann-Whitney U test  





1.3. Serum cytokine levels in NIU patients and controls 
As for cytokine evaluation (Fig. 5), a tendency for increased levels of IL-17A was found in the NIU group 
(p=0.08) compared to healthy controls (Fig. 6). No other differences were observed for the other 
cytokines evaluated. Again, we performed similar comparisons for the HLA-B27-associated subgroup. 
However, no differences were encountered in these comparisons for any of the cytokines evaluated.  
We then assessed how cytokine levels correlated to the cellular subsets studied. As for the control 
group, only a positive correlation was observed between TGF-β levels and the percentages of total CD4 
Tregs (r=0.604; p=0.017).  Interestingly, the NIU group presented a distinct profile of correlations. We 
observed a negative correlation between IL-10 levels and the percentages of memory Tregs in NIU 
patients' peripheral blood (p=0.030; R=-0.411). This correlation was also present in the HLA-B27-
associated uveitis subset (r=-0.411; p=0.007). Similarly, we observed a tendency for a negative 





Fig. 5 -. Representation of serum cytokine levels measurement by multiplexed flow cytometry. (A) Identification 
of IL-17A (dark red) and IL-10 (red) CBA beads. (B) Determination of IL-17A and IL-10 serum sample 










Fig. 6 - Scatter dot plot (median with IQR) of serum IL-17A levels in NIU and HC groups. NIU, Non-infectious 
uveitis; HC, Healthy Controls. 
 
Regarding the evaluated pro-inflammatory cytokines, a positive correlation between IL-17A levels and 
the absolute counts of memory Tregs was found (r=0.465; p=0.013) in the NIU group (Fig. 7-A). We 
also observed a positive correlation between TNF-α and the absolute counts of both total memory 
Tregs and CD39+ memory Tregs (r= 0.418; p=0.027) in the NIU group (Fig. 7-B).  
The inflammatory (TNF-α + IFN-ɣ + IL-17A) /anti-inflammatory (IL-10 + TGF-β) cytokine ratio showed a 
positively correlation with the absolute counts of both memory Tregs and CD39+ memory Tregs in the 
NIU group (r=0.406; p=0.032). In line with this, the IL-17A/IL-10 ratio was also positively correlated 




































Fig. 7 - Memory Tregs counts correlations with IL-17 (A) and TNF-α (B) serum levels in NIU group. Spearman’s 
correlation coefficients and p values are indicated. NIU, noninfectious uveitis. 
 
1.4. Age and T-lymphocyte subsets and Cytokine levels 
Since the mean age in both the patient and control group was similar (47.2 for patients and 44.7 for 
controls) but with a significant interval between minimum and maximal ages included (24-80 for 
patients and 20-86 for controls), we further separated both the patient and the control groups in two 
subsets -bellow (patients n=15, controls n=10) and over (patients n=14, controls n=5) 45 years old and 
compared cytokine levels as well as T lymphocyte subpopulations. We found a significant increase in 
total memory CD4+ T-cells in NIU patients younger than 45 years-old that was not present in controls 
(p=0.009), as well as an increase in IFN-ɣ levels (p=0.004). 
 
1.5. IL-17A levels and T-lymphocyte subsets, and other Cytokine levels 
As to evaluate IL-17A levels in NIU-patients, we separated both patients and controls into two groups- 
bellow (patients n=14, controls n=10) and over 2.17 pg/mL (mean + S.E.M. for IL-17A levels in the 
control group) (patients n=15, controls n=5). We analyzed possible correlations with T lymphocyte 
subsets and other cytokine levels in peripheral blood and found that patients with higher IL-17A levels 
also showed higher serum concentrations of memory (p=0.001) and naïve (p=0.003) Tregs as well as 
higher TNF-α (p<0.0001) and IFN-ɣ (p=0.016) levels. 





1.6. Anterior Chamber cellular reaction or Vitreous haze severity and T-Lymphocyte 
subsets and Cytokine levels 
Patients were further divided according to inflammatory cell reaction in the anterior chamber or 
vitreous as per standardization of uveitis nomenclature (SUN) and National Eye Institute (NEI) grading 
systems [25, 26] in two groups: (1) High severity (flare grade >2+ cell reaction or vitreous haze> 2+); 
(2) Low severity: flare grade <= 2+ cell reaction or vitreous haze<= 2+). 
Sixteen patients were included in the NIU-high severity group (HLA-B27-associated uveitis, n=12; BD, 
n=1; TINU, n=1; idiopathic disease, n=2) and thirteen in the NIU-low severity group (HLA-associated 
uveitis, n=8; BD, n=2; VKH, n=2; idiopathic disease, n=1). (Table XXIII) 
Comparing to controls, there was a tendency for increased memory Treg counts in the NIU-low severity 
group (p=0.053), but with no difference in CD39+ memory, Treg counts. There were also no differences 
in both these subsets between NIU-high severity patients and healthy subjects. Moreover, when 
analyzing percentages of Treg subsets within total Tregs, a tendency for higher levels of naïve Tregs 
(p=0.068), lower memory Tregs (p=0.068), and CD39+ memory Tregs (p=0,062) were also present in 
the NIU-low severity group compared to High severity patients.  
Regarding serum cytokine levels, a tendency for higher IL-17A concentrations was also found in the 
NIU-low severity group when comparing to controls (p=0,06).  
Finally, in the serum of NIU-low severity patients, positive correlations were found between IL-17A and 
TNF-α levels and memory Treg (respectively, r=0.767; p=0.005 and r=0.826; p=0.002) and CD39+ 
memory Treg counts (respectively, r=0.586; p=0.049 and r=0.714; p=0.012). As for the NIU-high 
severity group, a negative correlation was found between serum IL-10 levels and both percentages of 
total Tregs and memory Tregs (respectively, r=0.518; p=0.042 and r=0.553; p=0.029). (Fig. 8) 
 




























Fig. 8 - Correlation between serum cytokine levels and the distribution of Tregs subsets in NIU patients with low 
severity (A) and NIU patients with high severity (B). Spearman correlation coefficients and p-values are indicated. 





2. T-Lymphocyte Regulatory Subsets and Inflammatory Cytokine Levels after 
Treatment of Non-Infectious Uveitis 
2.1. Patients Demographics and Clinical Characteristics  
A total of 15 patients with a clinical diagnosis of active NIU were recruited. The diagnosis included 
idiopathic disease, HLA-B27-associated uveitis, BD, and VKH disease. Fifteen healthy sex and age-
matched healthy subjects were selected as controls. Table XXIV summarizes the features of the study 
population. 
Table XXIV. Characteristics of the study population. 
Patient Age Sex Diagnosis  Systemic Treatment 
1 62 M HLA-B27-associated No 
2 35 F HLA-B27-associated No 
3 29 F HLA-B27-associated No 
4 31 M HLA-B27-associated No 
5 62 F HLA-B27-associated No 
6 49 F HLA-B27-associated No 
7 49 M Vogt-Koyanagi-Harada Prednisolone, Cyclosporine 
8 37 F Vogt-Koyanagi-Harada Prednisolone, Cyclosporine 
9 36 M HLA-B27-associated Prednisolone 
10 72 F HLA-B27-associated Prednisolone 
11 41 M HLA-B27-associated Prednisolone 
12 42 M Behçet Disease Prednisolone, cyclosporine, 
adalimumab 
13 53 F Behçet Disease Prednisolone, azathioprine 
14 58 F Idiopathic No 
15 50 M Idiopathic No 
 
All patients were treated with topical corticosteroids and cycloplegics. In three cases of HLA-B27-
associated uveitis and the two cases of BD and VKH, patients also received therapy with systemic 
corticosteroids (prednisolone). Immunosuppressive therapy with cyclosporine A or azathioprine was 
necessary for the BD and VKH patients. In one case of BD, adalimumab was also initiated.  
Patient demographics were seven males and eight females, with an average age of 47 years (range, 
29-72 years). Control demographics were as follows: 8 males and 7 females, with an average age of 
44.7 years (range, 20-86 years old). 





2.2. Characterization of Regulatory T-Lymphocyte Subsets in NIU Patients and Controls  
Fifteen NIU patients were evaluated before and after treatment and compared to controls at both time 
points. Only thirteen NIU patients had flow cytometry evaluations (Table XXV and XXVI).  
 
Table XXV. Comparison of T cell subsets absolute counts in NIU AT, NIU BT, and control group 
NIU: Non-infectious Uveitis; NIU BT: NIU before treatment; NIU AT: NIU after treatment; IQR:  interquartile range. 




Table XXVI. Comparison of percentual values of T cell subsets in NIU AT, NIU BT, and control group 
        Group's comparisons 




















Percentages, median (IQR)       
        Group's comparisons 
        





NIU BT vs. 
NIU AT 








Cells/µL, median (IQR)             






0,865 0,409 0,542 
CD4 T cells 723 (557) 935 (483) 671 (496) 0,435 0,183 0,636 
Naïve  208 (258) 285 (185) 228 (197) 0,937 0,917 1,000 
Memory 479 (232) 567 (253) 382 (324) 0,369 0,259 0,542 
Effector 10 (15) 9 (22) 9 (10) 0,741 0,991 0,451 
Tregs  69 (56) 70  (50) 57 (39) 0,166 0,146 0,852 
Naive Tregs 14 (14) 17 (14) 14 (16) 0,883 0,674 0,830 
CD39+ naive Tregs  1 (1) 1 (1) 2 (1) 0,424 0,469 1,000 
Memory Tregs 47 (33) 52 (24) 33 (33) 0,110 0,230 0,877 
CD39+ memory Tregs  28 (25) 26 (21) 26 (20) 0,759 0,865 0,989 
CD8 (CD4-) T cells  442 (265) 443 (303) 510 (380) 0,808 0,843 0,497 
Naïve 96 (118) 124 (134) 109 (133) 0,883 0,643 0,625 
Memory 179 (134) 187 (114) 183 (157) 0,580 0,643 0,735 
Effector 122 (223) 152 (134) 165 (118) 0,474 0,381 0,735 






0,609 0,519 0,831 





        Group's comparisons 




















Within CD3 T cells       







0,611 0,519 0,748 






0,608 0,517 0,787 
Within CD4 T cells       














0,409 0,359 0,455 
Effector 1,12 (2,36) 0,94 (2,03) 1,14 (2,95) 0,914 0,865 1,000 
Tregs  9,12 (2,71) 8,56 (3,54) 7,43 (1,22) 0,048 0,336 0,011 
Naive Tregs 1,84 (1,43) 1,72 (0,96) 1,81 (0,98) 0,973 0,717 0,376 
CD39+ naive Tregs  0,11 (0,12) 0,13 80,14) 0,21 (0,18) 0,091 0,221 0,625 
Memory Tregs 7,05 (2,67) 6,1 (3,12) 5,27 (1,18) 0,057 0,249 0,094 
CD39+ memory Tregs  3,87 (4,19) 3,3 (3,11) 3,23 (1,40) 0,300 0,795 0,244 






28,02 (7,22) 0,154 0,107 0,735 




71,98 (7,22) 0,155 0,107 0,735 







(15,89) 0,777 0,917 0,685 





















(13,95) 0,129 0,608 0,376 
NIU: Non-infectious Uveitis; NIU BT: NIU before treatment; NIU AT: NIU after treatment; IQR: interquartile range. 
Results are presented as medians and interquartile range, median (IQR). Statistically significant results are 
indicated in bold. *Mann-Whitney U test. #Wilcoxon signed-rank test. 
 
Thus, considering the flow cytometric analysis before treatment, patients showed increased 
percentages of total Tregs (p=0.048) compared to controls. Also, within total CD4+ T cells, there was a 
tendency for increased percentages of memory Tregs in NIU patients (p=0.057). No further statistically 
significant differences were observed when comparing the two groups.  





However, the introduction of therapy changed this scenario, with patients showing a reduction in Treg 
cell levels (p=0.011) after treatment. Moreover, when comparing the after-treatment patient group 
with the control subjects, no significant differences were observed in percentages or absolute counts. 
 
2.3. Serum Cytokine Levels  
Despite the alterations reported for the cellular subsets, when regarding inflammatory cytokine levels, 
we observed no differences towards controls in patients with a clinical diagnosis of active NIU.  
Nevertheless, lower levels of IL17A (p=0.030), as well as a tendency for lower levels of TNF-α (p=0.055), 
were present in patients after treatment (Fig. 8). Furthermore, the inflammatory (TNF-α + IFN-ɣ + 
IL17A)/ anti-inflammatory (IL10 + TGF-β) ratio also showed a significant reduction between both 
evaluations in the NIU group. 
 
Fig. 9 - Scatter dot plot (median with IQR) of IL17A and TNF-α serum levels before (1st) and after (2nd) treatment 
of NIU group. Differences were tested using the Wilcoxon signed-rank test. *P-value <0.05; ns: non-significative. 
 
3.  Cytokine Profiles in the Peripheral Blood and Aqueous Humor of Patients 
with Herpetic Uveitis 
Four patients with presumed HU and 8 controls were included. Table XXVII summarizes the 
demographic and clinical features of the HU group. One patient with a panuveitis associated with acute 
retinal necrosis was also included. All HU patients underwent anterior chamber puncture and AqH 
sampling, as previously described. Results of AqH by real-time PCR confirmed a VZV infection in all the 
cases tested. 





Regarding serum cytokines, there were no significant differences observed between patients and 
controls. In AqH samples however, patients showed increased concentrations of IL10 (p=0.018), TNF-
α (p=0.018) and IFN-ɣ (p=0.024).  
Interestingly, the levels of serum and AqH cytokines differ between the two groups. While controls 
presented higher levels of IL10, IFN-ɣ and TGF-β in serum samples compared to those found in AqH 
(respectively, p=0.001; p=0.002 and p=0.001), in the patients’ group, only TGF-β showed higher serum 
concentrations when compared to AqH (p=0.029), with comparable values for the other cytokines 
tested.  
Table XXVIII shows the results and comparison of cytokine levels in the serum and AqH of both groups. 
 
 









1 F 76 
Unilateral anterior uveitis; sectorial iris atrophy; 
diffuse KPs; elevated IOP None + VZV 
2 M 45 Panuveitis- acute retinal necrosis None + VZV 
3 F 84 Unilateral keratouveitis; sectorial iris atrophy; 
diffuse KPs 
None +VZV 
4 M 74 
Unilateral anterior uveitis; elevated IOP; cataract; 
diffuse KPs; diffuse iris atrophy 
None +VZV 
F- female; M- male; KPs- keratic precipitates; IOP- intraocular pressure; VZV- varicella-zoster virus; PCR- 
polymerase chain reaction. 
 
Table XXVIII. Comparison of cytokine levels in Herpetic Uveitis patients and controls. 
























































0,18 0,91 - 0.018 - - 


















1861 374 - - 0.001 0.029 
HU, Herpetic Uveitis; IQR, interquartile range; AqH- Aqueous humour Mann-Whitney nonparametric U test was 
used for group's comparison. Results are presented as medians and interquartile range, median (IQR). 


















NIU can be associated with systemic autoimmune or inflammatory diseases like BD, ocular sarcoidosis, 
and VKH disease. HLA-B27-associated uveitis is the most common cause of acute anterior NIU, and 
patients with this condition may present with isolated uveitis or with an axial spondyloarthropathy. 
Treg cells are essential for regulating immune responses and have a potential suppressive role in 
disease activity. They can be subdivided into two different populations: thymic and peripherally-
derived and are responsible for the production of anti-inflammatory cytokines, which include 
transforming growth TGF-β and IL-10. 
FOXP3 is a characteristic marker of Treg cells and has been used in various studies analyzing Treg 
activation (218), but since it is an intracellular molecule, its detection requires fixation and 
permeabilization of cells. Several authors have proposed using the co-expression of CD4 and CD25 
associated with the absence, or the low expression of CD127 to identify the Treg subpopulation since 
a good correlation between these two phenotypes was previously reported (220, 267). Besides CD25, 
CD39 is also predominantly expressed on CD4+ FOXP3+ T-cells with an expression level proportional 
to FOXP3 (223, 268).  
In this study, we defined Tregs as CD3+CD4+CD25+CD127- cells while also analyzing its memory and 
naive subsets and CD39 expression in patients' peripheral blood with active NIU, including a subset of 
20 patients with HLA-B27-associated uveitis. Several studies have found decreased levels of Treg cells 
in patients with active uveitis from various causes (91-93), which led to a growing interest in 
establishing these cell populations as a biomarker in uveitis and possibly as a future therapeutic target 
(257). Moreover, a recent study further analyzing the frequency of CD4+CD25+FOXP3+ cells in patients 
with active uveitis and immunosuppressed patients in sustained clinical remission also found that 
TIGIT+ Tregs, T-bet+ Tregs, and the ratio of Tregs to Th1 cells were all significantly higher in remission 
NIU patients compared with patients with active uveitic disease (269). 
TIGIT is a co-inhibitory molecule expressed by Tregs associated with the selective inhibition of Th1 and 
Th17 responses (270), while the expression by Tregs of the effector CD4 T-cell transcription factor T-
bet has also been associated with Th1 suppression (271).  
Nevertheless, results have been conflicting, as some authors have found no differences (238, 239) or 
even increased (272) Treg levels in patients with active disease.  





In BSCR, an autoimmune disorder causing chronic inflammation of the posterior segment of the eye, a 
case-control study assessing Treg cell levels in the peripheral blood of patients with active disease 
found that the percentage of CD4+CD25+FOXP3+ Tregs was significantly lower when compared to 
controls but with no difference between CD4+CD25+ Tregs in both groups (256). However, another 
study with BSCR patients found that the proportion of CD4+CD25hiCD127low T cells was higher in 
patients than in controls (240). The authors suggested that Treg function rather than frequency needed 
to be studied.  
In the present work, when studying CD4+CD25+CD127- cell levels in NIU patients, we did not find 
significant differences from controls, although this may be related to a different strategy used to 
characterize Tregs.  
A recent study has also assessed different Treg subsets in autoimmune disease and found that the Treg 
compartment of patients with T1D Tregs contained a higher percentage of memory Tregs than healthy 
controls (234). When analyzing the CD39 expression of these Treg subpopulations, the same authors 
observed a decreased expression of this surface marker in memory Tregs, concluding that this may 
impair their suppressive function. A lower expression of CD39 in Tregs was also found in patients with 
active IBD (273).  
To our knowledge, the memory Treg subpopulation and respective CD39 expression have never been 
studied in NIU. In our patients, there were no significant differences in memory Treg levels (percentage 
and absolute counts) between patients and controls. However, when further analyzing patients with a 
lower grade of anterior chamber or vitreous inflammatory cellular reaction, we found a tendency for 
higher memory Treg counts in these patients than controls with no respective increase in CD39+ 
expression.  
Moreover, when analyzing Treg levels after uveitis resolution and treatment, one would expect that 
Treg levels would increase. However, our results have shown a higher percentage of both total and 
memory Tregs in patients with active inflammation when compared to controls and no significant 
differences from controls after treatment. It is interesting that although there were increased 
percentages of total and memory Tregs in patients with active disease, there was no significant 
difference between groups regarding CD39 expression, which may lead us to speculate whether these 
cells maintain their normal suppressive function.  





Our results do not support the role of total Treg frequency alone as a uveitis biomarker, and since, to 
our knowledge, these are the first studies addressing Treg naïve and memory subsets and respective 
CD39 expression in the peripheral blood of NIU patients, further studies are needed to elucidate this 
matter.  
Because of the heterogeneity and rarity of the uveitis entities included, activity of the disease and the 
different strategies used to characterize Tregs, we think that a larger multicenter study evaluating total 
Treg frequency as well as their naïve and memory subsets, CD39 and FOXP3 expression could be useful 
in establishing (or not) Tregs as biomarkers for NIU or even as future therapeutic targets. This may be 
of particular interest for CD39 expression, especially in the Treg memory subset, since this surface 
marker expression seems to be, as well as FOXP3, closely related to normal Treg immunosuppressive 
function through the CD39-CD73-adenosine pathway. This specific and activated Treg subset could be 
useful as a therapeutic target in auto-immune diseases, and recent work has shown, for example, that 
oral treatment with Polysaccharide A derived from the commensal Bacteroides fragilis, significantly 
increased the expression of CD39 on the surface of FOXP3+Tregs in addition to in vitro enhancement 
of CD39+FOXP3+Treg frequency (274). This expansion of a CD39+FOXP3+Treg subset could help 
establish a new paradigm in the treatment of several auto-immune diseases, including NIU. 
We also observed a negative correlation between IL-10 levels and the percentages of memory natural 
Tregs in NIU patients' peripheral blood, including in the HLA-B27-associated subgroup. A tendency for 
a negative correlation was also found for TGF-β and the percentages of total CD39+ Tregs in the NIU 
group.  Although IL-10 and TGF-β are suppressive cytokines and produced by Tregs, this may be 
explained by the fact that all these patients were in a very early stage of disease and Treg induction or 
that there is, in fact, an impaired regulatory cytokine production by Tregs in NIU patients. 
Regarding inflammatory cytokine expression, a tendency for IL-17A elevation was found in the NIU 
group (p=0.08), and it would have been interesting to study CD4+IL-17+ T cells frequency in these 
patients. The Th17/Treg ratio may be more specific for disease activity than isolated Treg levels, and 
further studies can warrant its usage as an active disease biomarker. 
Although we did not have data on Th17 cell levels, when analyzing the inflammatory (TNF-α + IFN-ɣ + 
IL-17A)/anti-inflammatory (IL-10 + TGF-β) cytokine ratio and the IL-17/IL-10 ratio, we did find a positive 
correlation between these ratios and the absolute counts of memory Tregs in the NIU group. We also 
found that higher IL-17A levels were associated with higher levels of memory and naïve Tregs, as well 
as higher serum concentrations of TNF-α and IFN-ɣ. 





This scenario may suggest induction of Treg cells in an effort to suppress cytokine production in early 
stages of intraocular inflammation, an impaired memory Treg function, or even activation of a specific 
IL-17-producing peripheral Treg subset, as observed in other conditions, including inflammatory and 
infectious diseases (275). Although adaptative Tregs exert their suppressive effect via the production 
of anti-inflammatory cytokines such as IL-10 and TGF-β, a distinct population of peripheral Treg cells 
that are FoxP3+ and produce IL-17 has already been identified in patients with Crohn’s disease (276) 
although, to our knowledge, this has never been described in uveitis.  
Nevertheless, evaluation of Th17 levels could have given further insight on this correlation between 
IL-17 and memory Tregs. Finally, we have observed a positive correlation between TNF-α and the 
absolute counts of both total memory Tregs and CD39+ memory Tregs in the NIU group. Together with 
IL-17A, TNF-α is a key cytokine in uveitis pathogenesis (157, 238, 277), and, understandably, it may 
show an elevated concentration when there are active disease and memory Treg upregulation.  
Accordingly, our results have thus shown a reduction in IL17A and TNF-α levels after uveitis resolution, 
as well as a reduction in the inflammatory/anti-inflammatory cytokine ratio. Although previous works 
have studied the total Treg cell frequency in active disease, there are few data evaluating individual 
Treg subsets as well as cytokine levels after treatment. Since we have evaluated patients before and 
after treatment, our results reinforce the notion that inflammatory cytokines like IL17A are 
fundamental in the disease pathogenesis and may represent a more tailored approach or treatment 
option in patients not responding to classical immunosuppression.  
So far, IL-17 increased expression and dysregulation seem to be particularly important in the 
physiopathology of auto-immune conditions like psoriasis  
 (278, 279) and ankylosing spondylitis (280, 281)  and novel therapeutic strategies based on 
neutralization of IL-17 have had encouraging results (282-286).  
However, results of clinical trials with the anti-IL-17 antibody Secukinumab in CD (287), RA (288) and 
refractory posterior NIU (136) have shown this drug to be ineffective or only partially effective, even 
though there is a strong body of evidence suggesting a pivotal role of IL-17 in the disease pathogenesis 
of CD (289), RA (290) and NIU  (107, 112, 113, 116).  





In the clinical trials on the efficacy and safety of secukinumab in the treatment of NIU, patients with 
Behçet's uveitis (SHIELD study); patients with active, noninfectious, non-Behçet's uveitis (INSURE 
study) and patients with quiescent, noninfectious, non-Behçet's uveitis (ENDURE study) were enrolled, 
but the primary endpoint for each study was not met, which led to early trial termination (136). 
Nevertheless, the secondary efficacy data from these studies suggest a beneficial effect of 
secukinumab in reducing concomitant immunosuppressants' use.  
Our study results support and reinforce the role of IL-17 in NIU, and although secukinumab did not 
show efficacy in uveitis treatment, other anti-IL-17 antibodies may be better alternatives for IL-17 
blockade and NIU treatment.  
Ixekizumab is a humanized monoclonal antibody against IL-17A currently approved for psoriasis, 
arthritic psoriasis, and ankylosing spondylitis. Brodalumab is a recombinant, fully human monoclonal 
antibody that binds with high affinity to the interleukin 17 receptor (IL17R) and is approved for treating 
moderate-to-severe chronic plaque psoriasis. As it is well known that different anti-TNF-α antibodies 
have different efficacies and safety profiles in NIU treatment (291), it seems reasonable to assume 
that, given the amount of evidence demonstrating the importance of IL-17 in NIU pathogenesis, these 
different antibodies targeting the IL-17 pathway could also be studied for uveitis treatment (292).  
There are NIU patients that do not respond to classical immunosuppressants or to anti-TNFα therapy, 
and therefore in these patients, it is vital to find drugs that target alternative pathways, further 
exploring the possible role of antibodies that target the IL-17 pathway (IL-17A or the IL-17 receptor). 
Additionally, monitoring IL-17 serum levels can also be an interesting option for patients with 
refractory NIU in whom there are doubts regarding current treatment efficacy. 
Finally, our results in NIU patients have also shown a reduction in TNF-α levels after uveitis resolution. 
Along with IL-17A, TNF-α is a crucial cytokine in uveitis pathogenesis (156, 293), and there is a growing 
experience in managing refractory NIU with anti-TNF-α immunomodulatory treatment (291). In EAU, 
it has been shown that TNF-α inhibition improves intraocular inflammation through Th1 effector 
response suppression (157) and its neutralization in the afferent phase of the disease, reduces EAU 
disease scores, IRBP-specific cell proliferation, and expression of Th1, Th2, and Th17 cytokines (294). 
 These pre-clinical observations supported the completion of three clinical trials analyzing the efficacy 
and safety of adalimumab, the first fully human anti-TNFα monoclonal antibody, in patients with 
noninfectious intermediate, posterior, or panuveitis. These trials results found that adalimumab was 
associated with a lower risk of uveitic flare or visual impairment (163) and led to adalimumab's 
approval in posterior NIU. 





Overall, our study has several strengths, such as the pioneer characterization of Treg subsets and 
respective CD39 expression in NIU, the prospective analysis after uveitis treatment and resolution, and 
the analysis of the major inflammatory and anti-inflammatory cytokines profiles involved in uveitis. 
These features provide new insight into the role of Tregs and cytokine profiles in NIU. We think it can 
be beneficial for NIU patients' approach and future treatment since some do not respond to classical 
immunosuppressants and need novel therapeutic targets. 
Our study's main limitation is the small sample size, which can be attributed to the rarity of the uveitic 
disorders included and to our study design.  We only recruited patients presenting with their first 
intraocular inflammation episode who had not received either topical or systemic treatment. Our 
initial estimates included about 20 patients for each group (patients before and after treatment and 
controls). After recruitment, it was possible to increase the first group of patients to 29, even though 
we could only include 15 patients with inactive and controlled uveitis. Some patients completed our 
first evaluation but were then lost to follow-up and did not return to our clinic. 
Another limitation is the heterogeneity of uveitic conditions included in the present study. Among the 
active NIU patients included, three had an idiopathic disease, twenty had HLA-B27-associated uveitis, 
three had BD, two had VKH disease, and one had TINU. Although all these patients had uveitis as their 
primary complaint and clinical feature, ideally, each of these entities should be studied separately 
because they all have different immunological mechanisms culminating in intraocular inflammation. 
Taking this into consideration, we further isolated HLA-B27+ patients and compared it both to healthy 
controls and to other causes of NIU. However, no differences were found in both comparisons for any 
of the studied T-cell subsets or cytokine profiles.  
Moreover, since most patients had an untreated concomitant systemic disease at the time of inclusion, 
it is reasonable to assume that inflammatory cytokine serum levels (IL-17, TNF-α, and IFN-ɣ) were also 
affected by active systemic inflammation, and this too must be taken into consideration when 
interpreting our results. 





Regarding infectious uveitis, our initial aim was to analyze the peripheral lymphocyte subpopulations 
as well as local and peripheral inflammatory and anti-inflammatory cytokines in a group of patients 
with active infectious uveitis and compare them with normal controls. However, patient recruitment 
and inclusion for this group were particularly difficult because we could only include patients who, for 
clinical reasons, needed to confirm the etiology of their intraocular infection through anterior chamber 
puncture and AqH PCR analysis. Since we were only able to include four patients with a clinical 
suspicion of herpetic uveitis, we chose to focus on the local (AqH samples) and peripheral (serum) 
cytokines profiles, comparing them with eight normal controls undergoing cataract or refractive 
surgery, without a history of intraocular inflammation. 
In this preliminary work, we included three patients with anterior herpetic uveitis and one patient with 
acute retinal necrosis, all with a confirmed VZV-associated ocular infection, as well as eight healthy 
controls. Our results showed that while were no significant differences between patients and controls 
regarding serum cytokine profiles, there were increased concentrations of IL-10, TNF-α, and IFN-ɣ in 
the AqH samples of patients.  
Two previous studies have found similar results in viral uveitis, one including 14 patients (HSV- 8; VZV- 
5 and CMV- 1) (118) and other 5 patients (HSV- 2 and VZV-3) (189) who also underwent AqH cytokine 
analysis.  This IL-10 elevation in intraocular fluids suggests a possible role of IL-10 as a biomarker for 
intraocular viral infection and may be responsible for the persistent and recurrent character of herpetic 
uveitis.  
Although IL-10 is a well-known immunoregulatory cytokine, viruses have developed mechanisms by 
which they use IL-10´s anti-inflammatory mechanisms to evade effective T-cell responses, promoting 
viral tolerance and survival (295). As a result, viruses can persist for life in infected hosts possessing 
otherwise competent immune responses, and this may be the reason why herpetic viruses can be 
associated with persistent and recurrent uveitis.  
It is known that sustained IL-10 expression during immune priming or secondary responses can favor 
persistence or chronic infections, and it is this delicate balance between the inflammatory response 
crucial to virus clearance and the IL-10-mediated immune regulation necessary for T cell homeostasis 
and host tissue protection that may be subverted by viruses to allow replication and spreading (295). 
IL-10 may actually be a therapeutic target for the treatment of persistent viral infection since it has 
been shown that, in mice, its genetic removal or administration of an anti-IL-10 receptor antibody 
successfully restores the effector T-cell response and results in viral elimination (296).  





 In AqH samples, patients also showed increased concentrations of TNF-α and IFN-ɣ, once again with 
no significant differences from controls in serum cytokine levels. This intraocular elevation in IL-10 and 
inflammatory cytokine levels reflects the local immune response secondary to VZV infection and shows 
how a further in-depth analysis of AqH´s cytokine concentrations may help clarify the mechanisms of 
uveitis-related ocular damages and enable a better understanding of the disease pathogenesis, 










VI. CONCLUSIONS  
In this study, we aimed to characterize regulatory T cell frequency and subpopulations (with respective 
CD39 expression) in patients with NIU, as well as cytokine expression in patients with non-infectious 
and infectious uveitis.  We performed flow cytometric analysis of the peripheral blood of patients with 
active intraocular inflammation and compared them with healthy controls. Patients with non-
infectious disease were then revaluated after treatment. In infectious uveitis cases, cytokine profiles 
present in the aqueous humour were also evaluated.  
There were no significant differences between patients with active NIU and healthy controls regarding 
total Treg frequency, as well as their naïve and memory subsets and respective CD39 expression. These 
results do not support the use of total Treg frequency as a biomarker for active disease. 
When analyzing Treg levels before and after uveitis resolution and treatment, our results have shown 
a higher percentage of both total and memory Tregs in patients with active inflammation and no 
significant difference from controls after treatment. However, although total and memory Tregs were 
increased in NIU patients with active disease, there was no significant difference between groups 
regarding CD39 expression in Tregs, suggesting a possible Treg dysfunction rather than reduction.  
 IL-17 levels in the serum of NIU patients have shown an elevation of this inflammatory cytokine levels 
in active intraocular inflammation and a reduction with disease remission. These results are in 
accordance with our extensive literature review on the roles of IL-17 in the physiopathology of uveitis 
and reinforce the need for more clinical trials addressing the efficacy of anti-IL-17 antibodies in the 
treatment of NIU. 
 The results in NIU patients have also shown a reduction in TNF-α levels after uveitis resolution, 
highlighting the already known role of this cytokine in active intraocular inflammation and providing 
additional evidence on the rationale behind anti-TNF-α antibody treatment of NIU. 
In patients with a confirmed intraocular VZV infection, there were increased concentrations of IL-10, 
TNF-α, and IFN-ɣ in the AqH samples compared to healthy controls. While local TNF-α and IFN-ɣ 
expression may be related to the intraocular inflammation, IL-10 seems to be a candidate for 
viral/herpetic uveitis biomarker and, possibly, a target for local treatment of chronic or recurrent 
infection.  





VII. FUTURE PERSPECTIVES 
Uveitis is a potentially blinding disease affecting active young individuals. Its diagnosis can be 
particularly challenging since it can manifest itself by isolated intraocular inflammation or be 
associated with other systemic manifestations. It can also be infectious or non-infectious; chronic, 
acute, or recurrent; granulomatous or non-granulomatous and affect only the anterior segment of the 
eye, only the posterior segment, or the whole uveal tract. These unique features pose many difficulties 
when trying to establish the correct diagnosis, and there have been made extensive efforts to find 
novel biomarkers that can help in the differential diagnosis of non-infectious and infectious uveitis.  
There is also much to learn about the immune mechanisms behind uveitis, and this search for 
biomarkers can lead the way to find new treatment targets for patients with disease refractory to 
conventional drugs.  
Tregs have been a subject of extensive research in recent years, and there have been numerous studies 
addressing Treg frequency and function on various auto-immune diseases.  That was also the case for 
non-infectious uveitis, leading to the possible therapeutic potential of specific regulatory T-cell 
immunotherapy for the treatment of non-infectious uveitis. However, results addressing Treg 
frequency or function in several auto-immune diseases and in NIU have been conflicting.  
Our study results also do not support total Treg frequency alone as a biomarker for uveitis, but we 
think that additional work with a larger multicenter study in which patients can be further separated 
and analyzed according to different etiologies would be more elucidative.  After analyzing our results, 
it also seems clear that future studies on this subject must address Treg subsets along with total Treg 
frequency and CD39 expression, as well as FOXP3 expression, because natural Tregs have different 
subpopulations performing unique functions, and there may be different mechanisms of disease for 
each separate entity. 
We also would like to take a further insight into the relationship between Th17 cells and adaptative 
Tregs in uveitis because it seems to us that there is a sequenced interplay between these cells in both 
the active and resolution phase of uveitis.  
Rather than thinking of uveitis as an imbalance in one cellular subset or one cytokine leading to an 
isolated treatment strategy, it is possible to think of it as a dynamic sequence of events in which we 
could act differently in different stages of disease.   





Finally, considering our preliminary results in herpetic uveitis patients, we think IL-10 may be a viable 
intraocular biomarker for patients with persistent and recurrent uveitis associated with VZV infection. 
Since there is little published evidence concerning this matter, we intend to further expand the number 
of infectious uveitis patients included to either confirm these results and compare them with 
intraocular infection from other etiologies, including other herpes viruses (HSV- 1 and 2, CMV) and 
other causative agents like, for example, Toxoplasma gondii. Again, these are rare diseases, and since 
it is vital to analyze intraocular fluid samples in this setting, a multicenter study or a more extended 
recruitment period would be mandatory. 
In conclusion, this study in non-infectious and infectious uveitis aimed to characterize lymphocyte 
subpopulations and cytokine expression in uveitis in order to better understand the underlying 
immune mechanisms and contribute to finding new biomarkers for disease activity as well as novel 
treatment targets. It is only with medical investigation that we can move forward and become better 
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Table 1 - Demographic and clinical features for the HU group. 






PCR results  
1 F 76 Unilateral anterior uveitis; 
sectorial iris atrophy; 
diffuse KPs; elevated IOP 
None + VZV 
2 M 45 Panuveitis- acute retinal 
necrosis 
None + VZV 
3 F 84 Unilateral queratouveitis; 
sectorial iris atrophy; 
diffuse KPs 
None +VZV 
4 M 74 Unilateral anterior uveitis; 
elevated IOP; cataract; 
diffuse KPs; diffuse iris 
atrophy 
None +VZV 
F- female; M- male; KPs- keratic precipitates; IOP- intraocular pressure; VZV- varicella zoster virus; PCR- polymerase 
chain reaction. 
 
Table 2 - Comparison of cytokine levels in HU patients and 
controls. 


































































1861 374 - - 0.001 0.029 
HU, Herpetic Uveitis; IQR, interquartile range; AqH- Aqueous humour  
 
Mann-Whitney nonparametric U test was used for group's comparison. Results are presented as medians and 
interquartile range, median (IQR). Statistically significant results are indicated in bold.  
 
